Note: Descriptions are shown in the official language in which they were submitted.
CA 03138899 2021-11-01
WO 2020/227601
PCT/US2020/032022
TISSUE DERIVED POROUS MATRICES
AND METHODS FOR MAKING AND USING SAME
CROSS-REFERENCE TO RELATED APPLICATIONS
The present application claims the benefit of U.S. Provisional Application No.
62/845,015
filed on May 8, 2019, the entire disclosure of which is hereby incorporated by
reference herein.
FIELD OF THE INVENTION
The present invention relates generally to tissue derived porous matrices
useful for treating
wounds. More particularly, the present invention relates to biocompatible
resorbable matrices
useful as wound dressings or grafts and which are derived from donor tissue
and have pores for
enhancing wound healing and tissue remodeling when implanted into a patient.
BACKGROUND OF THE INVENTION
Wound treatment and healing have been studied for centuries. As the
understanding of the
body's healing mechanisms has increased, more effective techniques for
enhancing and
accelerating wound healing have been developed. Various techniques employed to
enhance and
accelerate wound healing include: irrigating and/or debriding the wound to
remove debris, toxins
and bacteria; removing excess fluids; supplying local and systemic antibiotics
and anesthetics;
applying a scaffold (e.g., natural, biologic, synthetic, etc.) to the wound to
provide a substrate for
new tissue growth; providing cells, growth factors or other proteins to the
wound; and supplying
other tissue supportive therapies such as cells, growth factors and other
proteins, to the wound site.
Combinations of such techniques are often applied to enhance wound healing.
CA 03138899 2021-11-01
WO 2020/227601
PCT/US2020/032022
Reduced (i.e., negative, subatmospheric, hypobaric, etc.) pressure therapy is
a successful
technique for promoting and enhancing wound healing in soft tissue wounds that
are slow, or fail,
to heal completely. Reduced pressure therapy, sometimes referred to as vacuum
assisted closure
(or "V.A.C."), generally involves application of a reduced pressure, i.e.,
less than the ambient
pressure, at the wound site with a magnitude and for a time period sufficient
to promote healing
and/or tissue growth. It is believed that the reduced pressure applied to a
wound site assists in
increasing perfusion of blood/oxygen and flow of fluids, evacuation of wound
exudates, and
migration of epithelial tissue towards and formation of new subcutaneous
tissue in the wound site.
When coupled with an open lattice sponge (e.g., having interconnected pores),
reduced pressure
wound therapy techniques also confer both macrostrain and microstrain (and
microdeformation)
to the area of tissue loss with significant well described wound healing
benefits. These beneficial
effects include, but are not limited to: mechanical reduction of the wound
size through tissue creep
and stress relaxation and tissue expansion of the periwound tissues
(macrostrain) as well as
microstrain which subjects the healing cells to microdeformation that
potentiates and upregulates
a number of beneficial cellular healing processes. Reduced pressure therapy
may be used alone, or
in combination with any of the aforesaid wound treatment techniques.
Reduced pressure therapy systems and methods generally involve placement of a
dressing
on or in a wound site, followed by application of reduced pressure to the
wound site using a
reduced pressure source in fluid communication with the wound site through the
dressing. The
dressing serves as a manifold which distributes the reduced pressure
throughout the wound site,
thereby promoting the flow and migration of fluids, epithelial tissue and
subcutaneous tissue from
healthy tissue into the wound site.
2
CA 03138899 2021-11-01
WO 2020/227601
PCT/US2020/032022
Dressings suitable for performing reduced pressure therapy generally include
at least a
porous component and a semipermeable (i.e., semiocclusive or impervious)
barrier component,
where the porous component is positioned, partially or fully, in direct
contact with the wound site,
often filling the wound site, and the semipermeable barrier component is
positioned to cover the
entire wound site, including the porous component. The semipermeable barrier
component tends
to have a sheet-like shape and is sealingly affixed about its perimeter to the
wound site. A conduit,
which passes through the semipermeable barrier component of the dressing and
onto the porous
component, provides fluid/air and pressure communication between the reduced
pressure source
and the wound site, through the dressing.
Early embodiments of devices and methods for practicing reduced pressure
therapy are
described in U.S. Patent Nos. 5,636,643 and 5,645,081, the disclosures of
which are hereby fully
incorporated herein by reference. Such early versions utilized dressings with
a porous component
made of materials which were not bioresorbable or remodelable in vivo with
biological tissues, or
were only partially so. This necessitated removal of the porous component from
the wound site
prior to complete healing. Furthermore, as part of the healing process, there
was often tissue
ingrowth which at least partially infiltrated the porous component so that,
when it was removed,
new and/or healthy tissue were also removed or damaged, thereby causing
additional trauma to the
wound site during healing and pain to the patient. For larger or deeper wound
sites, removal and
replacement of the porous component with a fresh new porous component (e.g.,
of a smaller size
or different shape which better fit the partially healed wound site) would be
performed repeatedly,
resulting in ongoing damage and trauma to the wound site, thereby potentially
slowing or retarding
the healing progress. Further it has been identified that the use of non-
resorbable foams have a risk
for erosion when used in placement next to vital organs, nerves, or blood
vessels.
3
CA 03138899 2021-11-01
WO 2020/227601
PCT/US2020/032022
Improved devices and methods for practicing reduced pressure therapy, in which
at least a
portion of the porous component comprises a resorbable material providing
scaffold for new tissue
ingrowth which need not be removed, were developed. Several such improved
devices and
methods are described in U.S. Patent Nos. 8,163,974 and 8,197,806, the
disclosures of which are
also hereby fully incorporated herein by reference.
More particularly, U.S. Patent No. 8,163,974 describes modified dressings for
use with
reduced pressure therapy. One embodiment is a dressing which includes an open-
cell foam pad,
which is conventionally non-bioresorbable, with a bioresorbable cell-growth
enhancing matrix
implanted or superimposed thereon. U.S. Patent No. 8,163,974 discloses several
bioresorbable
materials suitable for the bioresorbable matrix, and even that, in a
particular embodiment, the open-
cell foam pad and the bioresorbable matrix may both be made of a bioresorbable
branched
polymer. Additionally, U.S. Patent No. 8,163,974 discloses another improved
dressing comprising
a non-bioabsorbable porous manifold component and a bioabsorbable porous
scaffold component
which is placed in contact with the wound site and facilitates cell
infiltration and tissue ingrowth.
This dressing also includes an intermediate release layer positioned in
between the manifold and
scaffold components and made of a "release" material which serves as a barrier
to tissue ingrowth
into the manifold component and dissolves upon hydration, thereby facilitating
separation of the
manifold component from the non-bioabsorbable porous manifold component. None
of the
bioresorbable materials disclosed for use in making any components of the
dressings described in
U. S . Patent No. 8,163,974 are tissues or derived from tissues recovered from
donors. The pores of
the bioabsorbable porous scaffold component described in U.S. Patent No.
8,163,974 have pore
sizes typically between about 50 and 500 microns, and more preferably between
about 100 and
4
CA 03138899 2021-11-01
WO 2020/227601
PCT/US2020/032022
400 microns. Pore sizes below 50 microns tend to inhibit or prevent tissue
ingrowth. In one
embodiment, the preferred average pore size of pores within the scaffold is
about 100 microns.
U.S. Patent No. 8,197,806 discloses a modified dressing purported to stimulate
cartilage
formation at tissue site when employed with reduced pressure therapy. More
particularly, the
dressing of U.S. Patent No. 8,197,806 is described as having a porous manifold
component for
distributing reduced pressure to a tissue site and a porous scaffold for
placement adjacent to the
tissue site. A chondrocyte and/or cytokine is also provided either directly to
the tissue site or within
the porous scaffold component. U.S. Patent No. 8,197,806 provides that either
or both of the
manifold and scaffold materials may be made of bioresorbable materials, and
also that the scaffold
component may be made of any of several synthetic and natural polymer
materials, including
processed allograft material, using any polymer processing techniques such as
melt-spinning,
extrusion, or casting. The pores of the bioresorbable porous scaffold
component of the dressings
described in U.S. Patent No. 8,197,806 have pore sizes ranging between 25 and
500 microns, such
as between 50 and 250 microns, or between 50 and 150 microns.
Further improvements to the dressings useful for treatment of wound sites to
enhance
healing and, particularly, for use with reduced pressure therapy, would be
welcomed by patients
and practitioners. For example, modified wound dressings having enhanced
ability to promote
effective and efficient wound healing, such as through improved and/or
accelerated cell
infiltration, proliferation, growth and activity continue to be sought.
SUMMARY OF THE INVENTION
The invention described and contemplated herein relates to a tissue derived
porous matrix
comprising a decellularized tissue, wherein the matrix is resorbable and has a
plurality of
5
CA 03138899 2021-11-01
WO 2020/227601
PCT/US2020/032022
interconnected pores which allow fluid flow through the matrix. When the
matrix is implanted, in
contact or proximity, with a wound site of a subject, the matrix at least
partially degrades, partially
remodels with native tissue at the wound site, or both, wherein no portion of
the matrix need be
removed from the wound site after being positioned with the wound. When
implanted in proximity
or contact with a wound site of a subject, fluid flow from the wound site and
through the matrix
occurs, with or without application of negative pressure, during healing at
the wound site.
In some embodiments, a biocompatible composition is provided which comprises
the
foregoing tissue derived porous matrix and one or more additional
biocompatible materials.
A method for producing a tissue derived porous matrix is also provided,
wherein the matrix
is resorbable and has a plurality of interconnected pores which allow fluid
flow through the matrix,
the method comprising the steps of: (A) obtaining a sample of tissue; (B)
optionally, reducing the
size of the tissue; (C) optionally, delipidating or demineralizing the tissue;
(D) decellularizing the
tissue; (E) optionally, disinfecting the tissue; (F) optionally, combining a
solvent with the tissue;
(G) optionally, placing the tissue in a container or mold; (H) forming or
modifying pores; (I)
optionally, drying the tissue; (J) optionally, crosslinking or other
stabilizing of the tissue; (K)
optionally, drying the crosslinked tissue; and (L) optionally, disinfecting
the crosslinked tissue. In
some embodiments of the method, the tissue comprises one or more tissue types
selected from
dermis, placental, adipose, fascia, and combinations thereof.
In some embodiments of the method for producing a tissue derived porous
matrix, the step
of disinfecting the tissue (E) comprises sterilizing the tissue, either before
or after the drying step
(I), or both. In some embodiments of the method, the step of combining a
solvent with the tissue
(F) is performed prior to the drying step (I) and the solvent is water,
wherein a tissue and water
mixture is formed, and wherein the steps of forming or modifying pores (H) and
drying the tissue
6
CA 03138899 2021-11-01
WO 2020/227601
PCT/US2020/032022
(I) are performed concurrently by lyophilizing the tissue and water mixture.
In some embodiments
of the method, the method further comprises the step of formulating, by
mixing, attaching, or
otherwise combining, the tissue derived porous matrix with other materials or
other synthetic or
naturally-derived matrices.
A method for treating a wound is also provided which comprises implantation of
a tissue
derived porous matrix, in contact or proximity, with a wound site of a
subject, wherein the matrix
comprises a decellularized tissue having a plurality of interconnected pores
which allow fluid flow
through the matrix and the matrix is resorbable. when a portion of the tissue
derived porous matrix
has not been resorbed some period of time after implantation, the method for
treating a wound may
further comprise removing at least a portion of un-resorbed portions of the
matrix from the wound
site in a subsequent procedure. The period of time after implantation may be
at least about 7 days.
In some embodiments, the decellularized tissue is derived from one or more
tissue types
selected from dermis, placental, adipose, fascia, and combinations thereof
A wound dressing is also provided which comprises a porous component
comprising the
foregoing tissue derived porous matrix; and an semipermeable barrier component
sized and shaped
to cover the porous component and a wound site to be treated with the wound
dressing.
Another method for treating a wound which uses the foregoing wound dressing,
comprises:
placing of the porous component, in contact or proximity, with a wound site of
a subject; placing
the semipermeable barrier component over the porous component such that it
covers the porous
component and the wound; sealingly affixing the semipermeable barrier
component to healthy
tissue about a perimeter of the wound to create a pocket of limited
permeability; and applying
negative pressure to the to the pocket and causing fluid to flow from the
wound, through the tissue
derived porous matrix, and out of the pocket.
7
CA 03138899 2021-11-01
WO 2020/227601
PCT/US2020/032022
BRIEF DESCRIPTION OF THE DRAWINGS
The present invention will be further explained with reference to the attached
drawings, in
which:
FIG. 1 is a flowchart showing the basic steps in an exemplary method for
producing tissue
derived porous matrices in accordance with the present invention;
FIG. 2 is a flowchart showing several possible alternative exemplary
embodiments of the
method for producing tissue derived porous matrices;
FIG. 3 is a schematic diagram of the test chamber apparatus used to assess
fluid flow-
through of tissue derived porous matrices described herein;
FIG. 4 is a schematic diagram of a Negative Pressure Wound Treatment (NPTW)
System,
including the test chamber of Figure 3, which was used to assess fluid flow-
through of tissue
derived porous matrices described herein;
FIG. 5 is a flowchart showing the basic steps of an exemplary method for
producing tissue
derived porous matrices comprising placenta tissue (a placenta biosponge) in
accordance with the
present invention;
FIG. 6 is a flowchart showing the basic steps of an exemplary method for
producing tissue
derived porous matrices comprising dermis tissue (a dermis biosponge) in
accordance with the
present invention; and
FIG. 7 is a flowchart showing the steps of an exemplary method for producing
tissue
derived porous matrices comprising dermis tissue (a dermis biosponge) in
accordance with the
present invention;
8
CA 03138899 2021-11-01
WO 2020/227601
PCT/US2020/032022
DETAILED DESCRIPTION OF THE INVENTION
Detailed descriptions of one or more embodiments of the present invention are
disclosed
herein. It should be understood that the disclosed embodiments are merely
illustrative of the
invention which may be embodied in various forms. In addition, each of the
examples given in
connection with the various embodiments of the invention is intended to be
illustrative, and not
restrictive. Further, the figures are not necessarily to scale, and some
features may be exaggerated
to show details of particular components. In addition, any measurements,
specifications and the
like shown in the figures are intended to be illustrative, and not
restrictive. Therefore, specific
structural and functional details disclosed herein are not to be interpreted
as limiting, but merely
as examples for teaching one skilled in the art to variously employ the
present invention.
The tissue derived porous matrices described and contemplated herein (also
referred to
below as "biosponges") enhance wound healing when applied to a wound site
because, being
porous, they provide a three dimensional scaffold for tissue ingrowth while
allowing escape of
excess fluid from the wound site. The porous matrices described and
contemplated herein have a
.. lattice of pores and are compressible. This compressible nature and the
lattice of pores will confer
macrostrain and microstrain, respectively. These forces are known to improve
the rate and quality
of wound healing and, thus, are expected contribute to rapid de novo tissue
ingrowth into the tissue
derived porous matrix. Since they are tissue derived, the porous matrices are
also biocompatible
and remodel into native tissue, which means it is not necessary to remove or
replace them after
initial placement at the wound site, thus avoiding damage to newly formed
tissue during the healing
process, as well as additional manipulation, pain, risk of procedures to the
patient. Reducing the
need to repeatedly revisit a treatment site to remove previously implanted
matrices will provide a
more convenient, comfortable, and less resource (e.g., inpatient or outpatient
nursing care, home
9
CA 03138899 2021-11-01
WO 2020/227601
PCT/US2020/032022
health care, other health or personal care provider, etc.) intensive course of
therapy for the patient.
The tissue derived porous matrices are acellular and, therefore, lack
immunogenicity and are
highly biocompatible. Additionally, the tissue derived porous matrices will
provide needed bulk,
support, barrier function, and padding, for subjects having experienced prior
tissue loss and/or
destruction, regardless of the cause. The aforesaid characteristics and
benefits also make the tissue
derived porous matrices useful as dressings for reduced pressure wound
therapy.
The tissue derived porous matrices may also comprise a small or significant
percentage of
biocompatible non-tissue material, including but not limited to polymers
(natural or synthetic),
ceramics, metals, nature-derived or animal-derived biomaterials, more
specifically between 20 and
80%. The tissue derived porous matrices may also contain endogenous beneficial
substances such
as growth factors, extracellular matrix components, nutrients, biologically
active molecules,
vitamins, or integrins which facilitate various tissue healing and remodeling
mechanisms
including, without limitation, extracellular matrix production and deposition,
cell infiltration and
proliferation, pathogen barrier and reduction, and angiogenesis. Furthermore,
the tissue derived
porous matrices may be coated with, infused with, or otherwise include
exogenous substances or
materials, including without limitation, cells, growth factors, extracellular
matrix components,
nutrients, integrins, anti-microbial agents, anti-infective agents,
bacteriostatic agents, or other
substances such as, but not limited to, those which promote cell migration,
attachment,
proliferation, growth and activity. For example, without limitation, some
growth factors are known
and/or believed to expedite cell recruitment, modulate inflammation, etc.
Methods for making the
tissue derived porous matrices and using them for wound treatment are also
described herein
below.
CA 03138899 2021-11-01
WO 2020/227601
PCT/US2020/032022
While the aforesaid tissue derived porous matrices will be described in detail
hereinafter
as a particular embodiment useful for performing reduced pressure therapy
wound treatment, it is
not limited to such embodiments and uses. Rather, persons of ordinary skill
will recognize that the
tissue derived porous matrices are useful as dressings, grafts, scaffolds,
etc., applied to wound sites
and will facilitate and enhance wound healing even in the absence of reduced
pressure therapy.
Such uses generally include placement (i.e., implantation) of a tissue derived
porous matrix, as
described and contemplated herein, in contact or proximity, with a wound site
of a subject wherein
the matrix is resorbable and has a plurality of interconnected pores which
allow fluid flow through
the matrix. Such implantation of the tissue derived porous matrices allow and
facilitate fluid flow
from the wound site and through the matrix, with or without application of
negative pressure,
during healing at the wound site. Additionally, the tissue derived porous
matrices described and
contemplated herein are useful for treatment of a subject to restore, enhance,
add to, or replace
tissues in any area of the subject's body that requires support, restoration,
regeneration,
enhancement, or replacement.
In some embodiments, at least a portion of the tissue derived porous matrix
will be resorbed
some period of time after implantation (e.g., at least about 7 days, or at
least about 14, or at least
about 21 days, or at least about 6 weeks, or at least about 10 weeks, or up to
about 3 months, etc.)
at a wound site. In some embodiments, when a portion of the tissue derived
porous matrix has not
been resorbed some period of time after implantation (at the discretion of the
medical professional
treating the wound site), at least a portion (i.e., some or all) of such un-
resorbed portions may be
removed from the wound site in a subsequent debridement procedure, e.g.,
similar to debridement
of native endogenous tissue in a wound or autograft. Additionally, in some
embodiments such un-
resorbed portions may not be removed from the wound site, but rather, will
remain implanted at
11
CA 03138899 2021-11-01
WO 2020/227601
PCT/US2020/032022
the wound site. Whether or not to remove un-resorbed portions of an implanted
tissue derived
porous matrix is well within the ability and discretion of persons of ordinary
skill in the relevant
art (e.g., medical professionals). In some embodiments, at the discretion of
persons of ordinary
skill in the relevant art (e.g., medical professionals), at least a portion of
un-resorbed tissue derived
porous matrix may be removed from a wound site at any time after implantation
(i.e., even earlier
than about 7 after implantation), regardless of whether any portion (or none)
of the matrix has been
resorbed.
Furthermore, in some embodiments, treatment of a wound (or wound site) of a
subject
using tissue derived porous matrices may comprise: a first implantation
(placement in contact or
proximity with the wound) of a first tissue derived porous matrix in a
subject, and a second
implantation (placement in contact or proximity with the wound) of a second
tissue derived porous
matrix some period of time after the first implantation. In fact, some
embodiments of methods for
using the matrices described and contemplated herein may comprise multiple
implantations of
multiple such matrices at or near a wound of a subject. In some embodiments,
treatment of a wound
using tissue derived porous matrices may comprise: a first implantation
(placement in contact or
proximity with a wound site of a subject) of two or more tissue derived porous
matrices in a
subject. The two of more matrices may be implanted concurrently, sequentially,
or a combination
of both. As will be readily understood by persons of ordinary skill in the
relevant art, further
variations and combinations of the foregoing uses of the presently described
and contemplated
.. tissue derived porous matrices are possible and useful. As used herein, the
term "about" as applied
to a period of time after implantation means 18 hours.
The terms "wound" and "wound site" as used herein mean a place or location in
or on a
body where tissue has been damaged, lost or degenerated such as by trauma,
injury, disease,
12
CA 03138899 2021-11-01
WO 2020/227601
PCT/US2020/032022
infection, surgical procedure (e.g., resection, etc.) and the like. Several
diseases, traumas, injuries
and surgical procedures result in one or more of damage to, loss of, or
degeneration of body tissue,
thereby resulting in formation of wound sites, which may be located
externally, internally, or both.
For example, surgical removal of soft tissue tumors and masses often result in
the loss of bulk
tissue. Other surgical and cosmetic procedures can, to varying degrees, cause
tissue damage, loss
and/or degeneration which may impair functionality as well as aesthetic
appearance. Tissue
damage, loss or degeneration can also result from trauma, such as from blunt
force impacts and
weapon injuries, including accidental and intentional. Finally, several
diseases, including acute
and chronic infection and wasting disease, may cause significant damage to,
loss of and/or
degeneration of body tissue. Any place where body tissue has been damaged,
lost and/or
degenerated by any and all such circumstances and events are intended to be
included, without
limitation, within the meaning of "wound" and "wound site."
The terms "healing" and "wound healing" as used herein mean the process by
which
damaged, missing or degenerated tissue is repaired and or replaced by new
tissue. Wound healing
is currently understood to involve three general phases: inflammation,
proliferation, and
maturation. These phases tend to occur sequentially, but also often overlap
with one another. An
initial "inflammatory" phase, involving hemostasis and inflammation, is most
often the body's
reaction to tissue injury or damage. This is followed by a second phase during
which
epithelialization, angiogenesis, granulation tissue formation, and collagen
deposition typically
occur. The last phase tends to consist of maturation and tissue remodeling.
The three step wound
healing process is actually more complex than the aforesaid description would
seem to indicate,
but is generally accurate for most wounds, including superficial, deep and
chronic wounds, when
complete healing does occur. Wound healing is affected and often complicated
by local factors
13
CA 03138899 2021-11-01
WO 2020/227601
PCT/US2020/032022
such as ischemia, edema, and infection, as well as systemic factors including,
for example,
diabetes, age, hypothyroidism, malnutrition, and obesity.
The term "angiogenesis" as used herein means the origination and development
(i.e.,
growth) of new blood vessels, which typically begins with migration of
endothelial cells and
formation of new capillary blood vessels. Angiogenesis is necessary to meet
the increasing
metabolic requirements of new and existing tissue growth and enlargement, so
that such tissue has
an adequate blood supply for providing oxygen, nutrients and waste drainage.
This process is
essential for healing, growth, development, and maintenance of body tissues.
The rate limiting step of wound healing is often angiogenesis. In wound
healing,
angiogenesis is achieved by endothelial cell migration and sprouting of
capillaries into a wound
bed is critical to the regeneration of tissue at the wound site. Granulation
and tissue formation are
enabled and supported at the wound site by the nutrients supplied by such
capillaries. Impairments
in wound angiogenesis therefore may lead to chronic non-healing wounds.
Expression of the angiogenic phenotype is a complex process that requires a
number of
cellular and molecular events to occur in sequential steps. Some of these
activities include
endothelial cell proliferation, degradation of surrounding basement membrane,
migration of
endothelial cells through the connective tissue stroma, formation of tube-like
structures, and
maturation of endothelial-lined tubes into new blood vessels (inosculation).
Angiogenesis is
controlled by positive and negative regulators. In addition to endothelial
cells, cells associated with
tissue repair, such as platelets, monocytes, and macrophages, release
angiogenic growth factors,
such as vascular endothelial growth factor (VEGF) into injured sites that
initiate angiogenesis.
The term "scaffold" as used herein refers to a substance or structure used to
enhance or
promote the growth of cells and/or the formation of tissue. In the present
context of wound
14
CA 03138899 2021-11-01
WO 2020/227601
PCT/US2020/032022
treatment and healing, a scaffold is typically a three dimensional porous
structure that provides a
template for cell growth.
The term "tissue derived" as used herein to describe the porous matrices means
that they
comprise processed tissue produced by recovering tissue from one or more
donors and treating the
recovered tissue to remove blood, debris, bioburden, a majority of the
endogenous cells and
cellular material, so they essentially lack immunogenicity while retaining a
proportion of the
initially present, naturally formed physical structure of the tissue
sufficient to provide a three-
dimensional scaffold capable of infiltration by cells and ingrowth by new
tissue. A "majority of
the endogenous cells and cellular material" means greater than about 50 %, by
weight (wt%), of
the cellular DNA material, based on the total weight of the cellular DNA
material initially present
in the recovered tissue before processing. The recovered tissue may be
autogeneic (i.e., recovered
from the same individual as the intended recipient), allogeneic (i.e.,
recovered from a different
individual of the same species as the intended recipient), or xenogeneic
(i.e., recovered from an
individual of a different species as the intended recipient). Furthermore, the
recovered tissue may
be adipose, fascia, dermis, bone, cartilage/meniscus, muscle, tendon/ligament,
placenta (including
amnion, chorion, amniochorion, Wharton's jelly, and umbilical cord), placental
disk, and
combinations thereof.
As used herein, the term "porous" as used to describe the tissue derived
matrices means
that the matrices have a plurality of interconnected pores (i.e., small holes,
interstices, cells,
cavities or openings), at least a portion of which are in fluid communication
with one another such
that they allow fluid to flow therethrough and, therefore, also through the
matrices. The pores also
facilitate and enhance cell infiltration and tissue ingrowth into the matrices
during the wound
healing process. The size, shape, or interconnectivity of the pores may be
uniform, random, or
CA 03138899 2021-11-01
WO 2020/227601
PCT/US2020/032022
patterned, and may be modified to enhance or control one or more processes
such as, without
limitation, new tissue formation, tissue remodeling, cell infiltration and
proliferation,
angiogenesis, and host integration.
As will be readily understood and practicable by persons of ordinary skill in
the relevant
art, varying the size and shape of the pores, as well as the porosity can
produce variation and
control of the flow characteristics of fluid passing through the tissue
derived porous matrices.
Generally, the tissue derived porous matrices described herein have an average
pore size of from
about 75 microns to about 1500 microns, such as from about 400 microns to
about 600 microns.
Generally, the tissue derived porous matrices described herein have a porosity
of from
about 50 % to about 99 %, such as from about 80 % to about 99 %, or from about
80 % to about
90 %. This relatively high porosity should allow the attachment of
infiltrating cells to induce new
tissue formation, as well as allowing the pores to be seeded with cells of
desired type in advance
to promote formation of a desired tissue type.
The terms "resorbable," "absorbable" and "bioabsorbable" and their grammatical
variants,
are used herein interchangeably to describe matrices or grafts and means that
the matrices or grafts,
e.g., the material from which they are made, will degrade, remodel, or a
combination of both,
within a limited time period after implantation or placement in a biological
environment, such as
adjacent to, in contact with, or implanted in living tissue, which means that
the matrices or grafts
do not need to be removed after implantation or placement. After that limited
period of time, the
matrix or graft is no longer recognizable as existing in its initial form. A
resorbable matrix or graft
may be resorbed by any of a variety of mechanisms. For example, without
limitation, a resorbable
matrix or graft may be resorbed through the action of cellular activity, such
as through the action
of macrophages that break down the resorbable regeneration matrix. A
resorbable matrix or graft
16
CA 03138899 2021-11-01
WO 2020/227601
PCT/US2020/032022
may be resorbed after being broken down by mechanical, chemical, metabolic
and/or enzymatic
degradation. It will be understood by persons of ordinary skill in the
relevant art that the precise
mechanism of resorbability is not critical, so long as the break down products
of the regeneration
matrix can be resorbed by and/or excreted from the body. The limited period of
time for which a
particular resorbable matrix or graft exists after placement or implantation
in living tissue may be,
for example without limitation, hours, days, weeks, months or even years.
Typically, as also
understood by persons of ordinary skill in the relevant art, such limited
period of time will be
determined by various factors including the type of biological environment and
adjacent tissue,
the size or mass of the resorbable matrix or graft that is implanted, the
conditions present in the
biological environment (temperature, pressure, pH, etc.), as well as the size,
mass, density and
other characteristics of the resorbable matrix or graft. For example, without
limitation, the limited
time period during which a resorbable matrix or graft may exist after
implantation may be 1, 2, 3,
4, 5, 6, 7, 8, 9 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24,
25, 30, 35, 40, 45, 50, 55,
60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180
days, or more, or any
value therebetween, when placed in the biological environment. For example, it
is believed that,
as a practice application parameter, the limited time period during which a
resorbable matrix or
graft should exist after implantation is at least about 4-7 days to minimize
the need for placement
of additional dressings at the wound site (i.e., minimize dressing changes).
The term "reduced pressure" as used herein generally means a pressure less
than the
ambient pressure existing at a tissue site undergoing treatment. Most often,
this reduced pressure
will be less than the atmospheric pressure at which the patient is located and
includes, without
limitation., hypobaric, subatmospheric, and negative pressures. Similarly, the
reduced pressure
may be less than a hydrostatic pressure associated with tissue at the tissue
site. Although the terms
17
CA 03138899 2021-11-01
WO 2020/227601
PCT/US2020/032022
"vacuum" and "negative pressure" may be used herein to describe the pressure
applied to a wound
site, the actual pressure reduction applied may be significantly less than the
pressure reduction
normally associated with a complete vacuum. Reduced pressure may initially
generate fluid flow
in the wound site and surrounding tissue. As the hydrostatic pressure around
the wound site
approaches the predetermined desired reduced pressure, fluid flow may diminish
or essentially
cease, whereupon reduced pressure is maintained for some period of time.
Unless otherwise
indicated, values of pressure stated herein are gauge pressures. Similarly,
references to increases
in reduced pressure typically refer to a decrease in absolute pressure, while
decreases in reduced
pressure typically refer to an increase in absolute pressure.
The term "reduced pressure source" as used herein refers to any device, such
as a vacuum
pump, wall suction, etc., which is capable of producing a reduced pressure of
from about -0.1 mm
Hg to about -500 mm Hg and includes a flexible conduit for fluidly connecting
to a wound dressing
suitable for use to perform reduced pressure therapy for treating a wound. The
reduced pressure
source may operate continuously, or intermittently or cyclically such that
there are alternating
periods of application and non-application to the wound site. As will be
understood by persons of
ordinary skill in the relevant art, the reduced pressure source may also
include sensors, processing
units, alarm indicators, memory, databases, software, display units, and user
interfaces that further
facilitate the application of reduced pressure treatment to the wound site.
Additionally, the reduced
pressure source may have additional features and components, such as, without
limitation, one or
more additional inlets, outlets, or both, which are configured for connecting
additional conduits
for delivery of fluids to a wound site, such as for irrigation or instillation
of the wound site, or
flushing and cleaning of the reduced pressure source. The fluids may be any
fluid suitable for
18
CA 03138899 2021-11-01
WO 2020/227601
PCT/US2020/032022
accomplishing the intended purpose of delivering the fluid to the wound site
(e.g., rinse, cleanse,
perfusion) or to the reduced pressure source (e.g., rinse, cleanse,
disinfect).
The term "semipermeable" as used herein to describe a component of dressings
suitable
for wound treatment methods, including but not limited to reduced pressure
therapies, means a
component having a generally sheet-like shape, capable of providing or forming
a sufficiently air
tight pocket (e.g., containing a wound/porous component complex) at a wound or
other site to be
treated with the dressing (i.e., water vapor may pass through) such that
negative pressure applied
to the pocket facilitates and promotes controlled removal of fluids from the
wound or tissue site
and surrounding tissues. As used herein, the characteristic of "semipermeable"
includes both
relatively impervious (i.e., nonporous or have low moisture vapor
transmission) as well as
semiocclusive (i.e., moisture or vapor permeable). The semipermeable component
of such
dressings is sealingly affixed about its perimeter to the wound site, thereby
providing the pocket
of limited permeability at the wound site for controlled application of
reduced pressure, as
described herein. Thus, while the impervious component of the dressings need
not prevent passage
of absolutely all fluids and other matter therethrough, as will be understood
by persons of ordinary
skill in the relevant art, the less permeable this component is, the more
effective the application of
reduced pressure at the wound site will be.
The term "impervious" as used herein to describe a component of dressings
suitable for
use with reduced pressure therapy means a component having a generally sheet-
like shape and
being at least only semi-permeable such that transmission of at least liquid
fluids, and optionally
also gases, therethrough is essentially prohibited.
The following description of embodiments of dressings suitable for performing
reduced
pressure therapy treatment techniques describe the dressings as including
tissue derived porous
19
CA 03138899 2021-11-01
WO 2020/227601
PCT/US2020/032022
matrices and a second component which is impervious. Nonetheless, it will be
readily understood
by persons of ordinary skill in the relevant art that the second component for
such dressing may
be semipermeable, for example without limitation semiocclusive, and that the
degree of
permeability (i.e., semipermeable, impervious, semiocclusive, etc.) is
determinable by such skilled
.. persons based on the type of wound or other tissue site to be treated using
such dressings, with or
without application of reduced pressure, and the desired outcome of such
treatment.
Dressings suitable for performing reduced pressure therapy typically include
at least a
porous component and an impervious component, where the porous component is
positioned,
partially or fully, in direct contact with the wound site, often filling the
wound site, and the
impervious component is positioned to cover the entire wound site, including
the porous
component (and sometimes also a portion of the normal tissue surrounding the
wound site). The
impervious component of such dressings typically has a sheet-like shape
(though this is not
required) which is sized to extend beyond the edges of the wound site to
completely cover wound
site and porous component. The impervious component is sealingly affixed to
healthy tissue about
the wound perimeter or circumference using, for example without limitation, a
biocompatible
adhesive. This arrangement provides a region or pocket of limited and
restricted permeability at
the wound site for controlled application of reduced pressure to the wound
site and healthy tissues
adjacent thereto. Preferably, the impervious component is made of an
impermeable substance that
is flexible and permits the diffusion of water vapor (preventing vapor-lock)
but provides an air-
.. tight enclosure.
A reduced pressure source is affixed in fluid communication with the dressing
and wound
site via a conduit which passes through (or under) the impervious component
and at least partially
onto, or in contact or proximity with, the porous component of the dressing.
As will be recognized
CA 03138899 2021-11-01
WO 2020/227601
PCT/US2020/032022
by persons of ordinary skill, while an opening may be provided through the
impervious barrier
component to allow passage of a conduit and permit fluid communication between
the wound site
and the external environment (and/or a negative pressure source), the conduit
could also be passed
underneath the impervious component and the impervious component sealingly
affixed to the
wound site and the conduit with the conduit held against the subject proximate
the wound site in
a manner which minimizes fluid flow or seepage around the conduit. While the
amount and nature
of reduced pressure applied to a tissue site will typically vary according to
the application,
permeability of the semipermeable component, and other factors familiar to
persons of ordinary
skill in the relevant art, the reduced pressure will typically be between -5
mm Hg and -500 mm Hg
and more typically between -50 mm Hg and -200 mm Hg. The particular protocol
used in reduced
pressure treatment depends upon the location of the wound site, the reduced
pressure dressing, and
any pharmacological agents being utilized. Additionally, reduced pressure may
be a substantially
continuous or cyclical application such that it oscillates the pressure over
time.
Generally, the dressing may have the porous and semipermeable components
already
assembled, joined or integrally formed together, with or without other
additional optional
components, prior to placement on or in a wound site. Alternatively, one or
more of the porous,
semipermeable and other optional components may be separate from one another
and placed on or
in the wound site sequentially, with the semipermeable component completely
covering the wound
site and porous component, which is in direct contact with the wound site. The
dressing is often
sized and shaped to fit on or in the wound site. In some embodiments, the
dressing may be sized
and shaped to extend beyond the perimeter or area of a wound or tissue site to
be treated. The
tissue derived porous component of the dressing may also be serially applied
in layers either at the
21
CA 03138899 2021-11-01
WO 2020/227601
PCT/US2020/032022
time of initial application or with subsequent applications to add volume or
bulk to the treatment
area as needed.
The tissue derived porous matrices described herein are suitable for use as
the porous
component of a wound dressing and may comprise the entire porous component or
a portion
thereof. Furthermore, the porous component may comprise one or more portions,
sections or
layers, each comprising one or more tissue derived porous matrices, where the
tissue derived
matrices may have been produced from the same or different types of recovered
tissue.
The tissue derived porous matrices described herein are useful and beneficial
for treating
(i.e., placement in and near, with or without negative pressure apparatus and
techniques) various
types of wounds including, without limitation, chronic, acute, traumatic,
subacute, dehisced
wounds, partial thickness burns, ulcers, pressure ulcers, tunneling wounds,
exposed fistulas and
flaps. Additional types of wounds which may be beneficially treated using the
tissue derived
porous matrices described herein include surgical wounds such as, without
limitation, donor sites,
post-Moh's surgery, post-laser surgery, and podiatric (e.g., interventions,
amputations), cancer or
tumor removals or extirpations, and draining wounds.
As described above, the tissue derived porous matrices are substantially
acellular, which
means that the majority of the endogenous cells and cellular material (i.e.,
greater than 50 wt% of
the originally present cellular DNA material) have been removed from the
recovered tissue during
processing. Accordingly, in addition to providing a resorbable three
dimensional scaffold for cell
infiltration and new tissue ingrowth, the tissue derived porous matrices lack
immunogenicity and
are, therefore, highly biocompatible. In some embodiments, without limitation,
greater than about
80 wt%, or greater than about 90 wt%, or greater than about 95 wt%, of the
originally present
cellular DNA material has been removed from the tissue derived porous
matrices, which means
22
CA 03138899 2021-11-01
WO 2020/227601
PCT/US2020/032022
the matrices contain less than about 20 wt%, or less than about 10 wt%, or
less than about 5 wt%,
of their originally present cellular DNA material.
Additionally, the methods making the tissue derived porous matrices, which
will be
described in detail below, typically result in the matrices retaining
sufficient beneficial endogenous
substances which facilitate various tissue healing and remodeling mechanisms
including, without
limitation, extracellular matrix production and deposition, cell infiltration
and proliferation, and
angiogenesis. The ability of the tissue derived porous matrices to facilitate
angiogenesis and
support new tissue formation when used to treat wound sites with negative
pressure is believed to
be a benefit previously unseen and unrealized with previously available
negative pressure wound
.. dressings. The ability of the tissue derived porous matrices to be
optimized for cell infiltration and
tissue regeneration via tuned pore sizes, porosity, and degradation rate is
believed to be a benefit
previously unseen and unrealized with previously available standard wound
dressings.
Furthermore, the tissue derived porous matrices may be coated with, infused
with, or otherwise
include exogenous cells, growth factors, extracellular matrix components,
nutrients, integrins, or
other substances such as, but not limited to, those which further promote cell
migration,
attachment, proliferation, growth and activity.
The tissue derived porous matrices may also include or be combined with one or
more
exogenous biocompatible materials, which may or may not also be biologically
active. Such
exogenous materials include, but are not limited to: polymers (natural and
synthetic), ceramics,
metals, other biomaterials, and combinations thereof. Combining the tissue
derived porous
matrices with one or more such additional materials may be performed, for
example without
limitation, by one or more of mixing, blending, layering, coating, and
otherwise contacting, and
may form a homogenous combination or not. Such combination with one or more
exogenous
23
CA 03138899 2021-11-01
WO 2020/227601
PCT/US2020/032022
materials may be performed for any of several reasons such as, without
limitation, modifying
handling characteristics or other properties (e.g., flowability, manual
shapability, moldability,
degree of shape retention or memory, cohesiveness, agglomeration, flowability,
porosity, etc. ), or
enhancing or adding functionality (adhesion to recipient, retention in or on
recipient, adding
exogenous tissue-forming potential, infection prevention, pH modification,
increasing mass and/or
available surface area, other bioactivity, etc.).
Ceramics suitable for combination with the tissue derived porous matrices are
biocompatible and include those known now and in the future such as, without
limitation,
aluminum oxides, calcium oxides, aluminosilicates, hydroxyapatites, tricalcium
phosphates,
polytetrafluro ethylene (PTFE) - carbon composites, zirconium oxides, silicon
carbides, titanium
nitrides, boron nitrides, carbides, and composites and combinations thereof
Metals suitable for
combination with the tissue derived porous matrices are also biocompatible,
and include those
known now and in the future such as, without limitation, titanium, chromium,
tantalum, zirconium,
magnesium, stainless steel, and alloys and combinations thereof.
Suitable natural and synthetic polymers are biocompatible and include those
known now
and in the future. The polymers may be biodegradable and present in
compositions with tissue
derived porous matrices in proportions selected to provide grafts having
various preferred rates of
degradation and resorption of the implant and the tissue derived porous
matrices. Suitable synthetic
polymers include, but are not limited to, bioabsorbable polymers such as
polylactic acid (PLA),
polyglycolic acid (PGA), polylactic-coglycolide acid (PLGA), and other
polyhydroxyacids,
polycaprolactones, polycarbonates, polyamides, polyanhydrides, synthetic
polyamino acids,
polyortho esters, polyacetals, degradable polycyanoacrylates and degradable
polyurethanes, as
well as a polylactide-coglycolide (PLAGA) polymer or a polyethylene glycol-
PLAGA copolymer.
24
CA 03138899 2021-11-01
WO 2020/227601
PCT/US2020/032022
Examples of natural polymers include, but are not limited to, proteins such as
albumin, collagen,
fibrin, and polyamino acids, oligosaccharides (e.g., chitosan), and
polysaccharides (e.g., alginates,
hyaluronic acid and its derivatives, heparin, and other naturally occurring
biodegradable polymers
of sugar units). The polymeric blend may also include, without limitation,
polycarbonates,
polyfumarates, and capralactones.
With now reference to Figure 1, a method for producing the tissue-derived
porous matrices
described above will now be explained. After obtaining a sample of tissue 112
having an
extracellular matrix, which may or may not involve recovering the tissue from
a donor, the method
for producing (manufacturing) a tissue derived porous matrix 100, requires
decellularizing 118 the
tissue to decrease or remove substantially all of the endogenous cells and
cellular material in the
tissue. The technique or method of decellularizing 118 the tissue is not
particularly limited and
may include any technique known now or in the future to persons of ordinary
skill in the relevant
art which does not completely destroy the structure of the extracellular
matrix of the tissue.
Optionally and typically, but not necessarily, performed prior to
decellularizing 118, the
method for producing the tissue derived porous matrix 100 may further include
the step of reducing
the size of the tissue 112, either by mechanical or chemical techniques known
now or in the future
to persons of ordinary skill in the relevant art,
Optionally and typically, but not necessarily, performed prior to
decellularizing 118, the
method for producing the tissue derived porous matrix 100 may further include
the step of
delipidating or demineralizing the tissue 116, using techniques known now or
in the future to
persons of ordinary skill in the relevant art, for decreasing the amount, or
removing substantially
all, of the lipids or the minerals, respectively, of the tissue. Whether
delipidating or demineralizing
the tissue 116 is performed will generally be determined according to the type
of tissue being
CA 03138899 2021-11-01
WO 2020/227601
PCT/US2020/032022
treated (e.g., adipose or bone, respectively) and the ultimate intended use of
the tissue derived
porous matrix.
Optionally and typically, but not necessarily, performed after decellularizing
118, the
method for producing the tissue derived porous matrix 100 may further include
the step of
disinfecting (i.e., reducing the microbial load of the tissue) 120, by
techniques known now or in
the future to persons of ordinary skill in the relevant art, for decreasing
the amount, or removing
substantially all, of the microbes, bacteria, and other infectious substances
from the tissue. Such
techniques may be, without limitation, chemical, mechanical, exposure to
radiation, etc., or any
combination thereof
Additionally, the method 100 may further comprise the step of combining the
tissue with
one or more solvents 122 such as, without limitation, water, saline, phosphate
buffered solution or
other salt solutions or biocompatible solvents known to persons of ordinary
skill in the relevant art
for resuspending, evenly distributing, increasing the volume of, or otherwise
altering the handling
and other characteristics of the resulting tissue derived porous matrix. The
step of combining the
tissue with one or more solvents is typically, but not necessarily, performed
after decellularizing
118. Optionally and typically, but not necessarily, performed after combining
the tissue with one
or more solvents 122, the method 100 may further include the step of placing
the tissue, or the
combination of tissue and solvent (and, optionally, additional endogenous
materials) in a container
or mold 124. The container or mold may, but is not required to, have a desired
or preselected shape
which is imparted to the tissue, such as after the combined tissue and solvent
are placed in the
container or mold and subjected to a drying step 128 and/or a crosslinking
step 130.
It is noted that, after decellularizing 118, the tissue may already have a
plurality of pores.
Optionally and typically, but not necessarily, performed after the
decellularizing step 118, the
26
CA 03138899 2021-11-01
WO 2020/227601
PCT/US2020/032022
method for producing the tissue derived porous matrix 100 may further include
performing one or
more pore formation steps 126. Such one or more pore formation steps 126 may
be performed by
any technique known now or in the future to persons of ordinary skill in the
relevant art, including
without limitation, those techniques described herein. The pore formation
steps 126 may be
performed to form (i.e., create) pores or modify existing pores in the tissue
and may be performed
more than once.
As will be described in further detail below, optionally and typically
performed after
decellularizing 118, the method for producing the tissue derived porous matrix
100 may further
include the step of drying the tissue 128, by any techniques known now or in
the future to persons
of ordinary skill in the relevant art, for decreasing the amount, or removing
substantially all of, the
moisture (e.g., water) from the tissue. The method 100 will often include such
a drying step 128,
which is typically, but not necessarily, performed by lyophilizing as
described in further detail
hereinafter. As is understood by persons of ordinary skill in the relevant
art, lyophilizing (also
referred to as lyophilization) typically involves two phases ¨ a freezing
phase and a drying phase.
The step of drying the tissue 128 may be performed while the tissue (with or
without a solvent
and/or additional exogenous material) is in a container or mold and may
accomplish shaping the
tissue into a desired shape (i.e., the shape of the container or mold).
Another drying technique may,
for example without limitation, comprise dehydrothermal processes, which
involve application of
heat under vacuum.
Optionally and typically, but not necessarily, performed after drying 128, the
method for
producing the tissue derived porous matrix 100 may further include the step of
crosslinking or
otherwise stabilizing the tissue derived porous matrix 130, using techniques
known now or in the
future to persons of ordinary skill in the relevant art, as will be described
hereinbelow. For
27
CA 03138899 2021-11-01
WO 2020/227601
PCT/US2020/032022
example, as will be recognized by persons of ordinary skill in the relevant
art, other stabilizing
techniques include, without limitation, heating and irradiation (e.g.,
exposure to gamma rays,
ultraviolet energy, electron beam ("e-beam") radiation, etc.). Whether
crosslinking or other
stabilizing 130 is performed will generally be determined according to the
type of tissue being
treated and the ultimate intended use of the tissue derived porous matrix. A
crosslinked or
otherwise stabilized tissue derived porous matrix may, optionally, be
subjected to a further drying
step 132, such as without limitation by lyophilizing. Additionally, a
crosslinked or otherwise
stabilized tissue derived porous matrix may, optionally, be subjected to a
further step of reducing
the microbial load 134, for example but not necessarily after a further drying
step 132. For
example, without limitation, after crosslinking 130 is performed, and after
further drying 132 is
performed, a terminal sterilization step (i.e., another reduction of microbial
load, or disinfecting
step) 134 may be performed by any technique known now or in the future to
persons of ordinary
skill in the relevant art.
Lyophilizing may be performed to accomplish the formation of pores (e.g., step
126), to
accomplish drying (i.e., step 128), to accomplish further or additional drying
(e.g., step 132), or a
combination of such steps 126, 128, 132. Thus, in some embodiments the step of
forming pores
126 may be the same as, or performed concurrently with, the step of drying
(128) by lyophilizing.
Without being limited by theory, it is believed that performing lyophilizing
within certain
parameters forms pores in a consistent and controllable manner, as will now be
described.
For example, prior to lyophilizing, the step of combining the tissue with a
solvent (122)
may include adding (combining) water (or another aqueous solvent) with the
tissue to form a tissue
and water mixture having a ratio of tissue to water of from about 1:99 to
about 99:1, based on 100
parts of total tissue and water mixture. This "excess" water facilitates
formation of water crystals
28
CA 03138899 2021-11-01
WO 2020/227601
PCT/US2020/032022
in the tissue during the freezing phase of lyophilizing, which are then
removed during the drying
phase of lyophilizing, leaving pores (i.e., vacant spaces) in the lyophilized
tissue. In some
embodiments when lyophilizing is performed to form pores in the tissue being
processed to make
a biosponge, the ratio of tissue to water may generally be from about 1:99 to
about 60:40, or any
ratio or value therebetween, such as from about 1:99 to 50:50, or from
about1:99 to 40:60, or from
about 5:95 to about 60:40, or from about 10:90 to about 60:40, or from about
10:90 to about 50:50.
The amount of water combined with the tissue (i.e., the ratio of tissue to
water) prior to
lyophilizing may vary according to the type of tissue used to make the tissue
derived porous
matrices (biosponges), as is determinable by persons of ordinary skill. For
example without
limitation, when the tissue type used is placental, the ratio of tissue to
water may be as low as about
1:99. For example without limitation, when the tissue type used is dermis, the
ratio of tissue to
water may be from about 1:99 to about 40:60, or any ratio or value
therebetween, such as from
about 10:90 to about 40:60, or from about 10:90 to about 30:70, or from about
15:85 to about
30:70.
In some embodiments when lyophilizing is performed to form pores in the tissue
being
processed to make a biosponge, the rate of freezing during lyophilizing (i.e.,
during the freezing
phase thereof) should typically be in a range from about 0.1 C / minute to
about 2 C / minute or
any range or value therebetween. For example without limitation, the rate of
freezing during
lyophilizing, may be from about 0.1 C / minute to about 2 C / minute, such
as from about 0.1 C
/ minute to about 1 C / minute, or from about 0Ø2 C / minute to about 0.5
C / minute, from
about 0.3 C / minute to about 0.4 C / minute.
In some embodiments when lyophilizing is performed to form pores in the tissue
being
processed to make a biosponge, the drying time for the drying phase of
lyophilizing should
29
CA 03138899 2021-11-01
WO 2020/227601
PCT/US2020/032022
typically be in a range of from about 720 minutes (0.5 days) to about 10,080
minutes (7 days), or
any range or value therebetween, such as from about 1440 minutes (1 day) to
about 10,080 minutes
(7 days), or from about 4320 minutes (3 days) to about 8640 minutes (6 days),
from about 7200
minutes (5 days) to about 8640 minutes (6 days). As is understood by persons
of ordinary skill in
the relevant art, the drying time may be even more than 7 days depending on
the dimensions of
the biosponge to be dried.
Figure 2 provides several possible alternative embodiments of the method for
producing
the tissue derived porous matrices 200 employing several of the above-
described steps in various
orders. All of these embodiments 200, as well as others, which will be
apparent to persons of
ordinary skill in the relevant art, are within the scope of the present
disclosure for performing the
method for producing the tissue derived porous matrices.
The method for producing the tissue derived porous matrices 100 may further
include one
or more packaging steps (not shown). The method 100 may also include one or
more combining
or formulating steps (not shown) whereby the tissue derived porous matrices
are mixed, attached
or otherwise combined with other materials including, without limitation,
cells, growth factors,
other substances (e.g., antibiotic, antimicrobial, pharmaceutically effective
compounds,
excipients, carriers, etc.), other types of synthetic or naturally derived
matrices (e.g., an adipose
derived porous matrix combined with a bone derived matrix or a synthetic
dissolvable, resorbable
matrix, etc.), and other types of materials (e.g., a resorbable monolithic or
mesh scaffold, etc.).
As is understood by persons of ordinary skill in the relevant art, a carrier
may be
biologically inert or inactive. A carrier may be biologically active, for
example, in a manner which
enhances the tissue-forming potential of the tissue derived porous matrices,
or the carrier may
provide or induce another biological activity, property or effect which may be
unrelated,
CA 03138899 2021-11-01
WO 2020/227601
PCT/US2020/032022
complementary or supplemental to the tissue-forming potential of the tissue
derived porous
matrices.
Suitable biocompatible carriers may be naturally occurring or derived
therefrom, or
synthetic, or a combination of such materials. Generally, suitable
biocompatible carriers include
for example, without limitation, buffered solutions, glycerol, hyaluronate,
polyethylene glycol,
stearates, cellulose-derived materials (e.g., chitosan, alginates,
hydroxypropyl cellulose (HPC),
carboxymethyl cellulose (CMC), hydroxypropyl methyl cellulose (HPMC), etc.),
and
combinations thereof Particularly suitable biocompatible carriers for use with
the tissue derived
porous matrices include, without limitation, hyaluronate, glycerol and
buffered solutions. In some
embodiments, the biocompatible carrier comprises sodium hyaluronate. In some
embodiments, the
biocompatible carrier comprises sodium hyaluronate and a buffered saline
solution. In some
embodiments, the biocompatible carrier comprises glycerol.
In some embodiments, the carrier includes at least one of an isotonic
solution, a sodium
chloride solution, lactated Ringer's solution, a phosphate-buffered saline
solution (PBS), platelet
rich plasma (PRP), bone marrow aspirate (BMA), and hyaluronic acid (HA) or a
derivative thereof
such as sodium hyaluronate. In embodiments, the carrier is a sodium chloride
solution at a
concentration of about 0.1% to about 1%. In some such embodiments, the sodium
chloride solution
is at a concentration of about 0.9%. In some embodiments, the carrier is a
mixture of sodium
hydaluronate and an aqueous solution. In some embodiments, the sodium
hyaluronate has a
molecular weight of from about 5.0 x 103 to about 3.0 x 106 Daltons, such as
from about 6.0 x 105
to about 3.0 x 106 Daltons and is mixed with an aqueous solution to form a
matrix-carrier mixture
having a viscosity ranging from about 1000 centipoise to about 275,000
centipoise, such as from
about 6,000 to about 275,000 centipoise. In some embodiments, the aqueous
solution of the carrier
31
CA 03138899 2021-11-01
WO 2020/227601
PCT/US2020/032022
comprising sodium hyaluronate is, for example without limitation, one or more
of water, saline,
phosphate buffered solution (PBS), isotonic saline, and the like.
In some embodiments, the carrier comprises thrombin. In some embodiments, the
carrier
comprises fibrin. In some embodiments, the carrier comprises glycerin. In some
embodiments, the
carrier comprises gelatin. In some embodiments, the carrier comprises
collagen. In some
embodiments, the carrier comprises lecithin. In some embodiments, the carrier
comprises a sugar.
In some embodiments, the sugar comprises a polysaccharide. In some embodiments
the carrier
includes a combination of two or more carrier components.
As will be understood and practicable by persons of ordinary skill in the
relevant art, where
one or more steps of the method 100 are described herein as being performed
"prior to" or "after"
another step of the method 100, such one or more steps may, but need not, be
performed
immediately prior to or after said another step, such that other steps may be
performed in between
such one or more steps and said another step. Additionally, while the method
100, 200 should
include at least the steps of obtaining a sample of tissue 112 and
decellularizing the tissue 118,
each of the "optional" steps described above may be performed, or may be
omitted from a
particular embodiment. The method for producing the tissue derived porous
matrices 100, 200, in
addition to the aforesaid obtaining and decellularizing steps 112, 118, may
include any
combination of the above-described optional steps 114, 116, 120, 122, 124,
126, 128, 130, 132,
134 and any one or more of the treatment steps 114, 116, 118, 120, 122, 124,
126, 128, 130, 132,
134 may be performed in any order and may be performed more than once.
Tissues recovered from donors (i.e., "recovered tissues") are processed using
a
combination of physical and chemical methods to produce a tissue derived
porous matrix of
defined dimensions, porosity, mechanical properties, and controlled resorption
rate. The method
32
CA 03138899 2021-11-01
WO 2020/227601
PCT/US2020/032022
further includes process steps for decellularization and, optionally, reducing
microbial/viral load.
In some embodiments, the method may further include partial or complete
drying, or dehydration,
to provide a final "dry" product. More particularly, a final "dry" tissue
derived porous matrix
contains less than about 20 wt% of water/moisture, based on the total weight
of the tissue derived
.. porous matrix, such as less than about 15 wt%, or less than about 10 wt %,
or less than about 8
wt%, or less than about 6 wt%, or less than about 5 wt% water/moisture. In
some embodiments,
the method does not include drying/dehydration and the tissue derived porous
matrices remain
hydrated, through packaging, storage and use, so that they need not be
rehydrated at the time of
use. Partially dry or undried tissue derived porous matrices contain greater
than about 20 wt% of
water/moisture, based on the total weight of the tissue derived porous matrix,
such as greater than
about 25 wt%, or greater than about 30 wt %, or greater than about 35 wt %,
The tissue derived porous matrices may be crosslinked and, in some
embodiments, such
crosslinked matrices contain more than about 20 wt% of water/moisture, based
on the total weight
of the tissue derived porous matrix. The crosslinked tissue derived porous
matrices may, in other
embodiments, be provided as a final "dry" product that contains less than
about 20 wt% of
water/moisture, based on the total weight of the tissue derived porous matrix,
such as less than
about 15 wt%, or less than about 10 wt %, or less than about 8 wt%, or less
than about 6 wt%, or
less than about 5 wt% water/moisture.
Without wishing to be limited, it is believed that tissue derived porous
matrices having a
compression force deflection (CFD) in a range of from about 2 kiloPascals
(kPa) to about 20kPa,
when a moisture saturated tissue derived porous matrix is compressed to at
least 50% of its original
uncompressed thickness, would be most familiar and useful to practitioners
(e.g., physicians,
surgeons, nurses, medical assistants, etc.). For example, where the recovered
tissue used to prepare
33
CA 03138899 2021-11-01
WO 2020/227601
PCT/US2020/032022
the porous matrices is dermis, a CFD of from about 2 to about 10 kPa would
typically be
acceptable, but where the recovered tissue is placental tissue, a CFD of up to
about 20 kPa would
likely be acceptable.
To maximize some of the above-stated benefits when used to enhance wound
healing,
when positioned in a wound site and subjected to reduced pressure in a range
of from about -50
mm Hg to about -200 mm Hg, it is believed that the tissue derived porous
matrices should maintain
at least 25% of their original mass and porous structure for a minimum of
about 96 hours.
The material of the biosponge can be derived from chemically solubilized,
mechanically
reduced or intact extracellular matrix (ECM) obtained from decellularized
tissue of the types
including, but not limited to, adipose, dermis, placental tissue, fascia,
bone, cartilage, muscle or
composite of adipose/fascia or adipose/dermis/fascia, or from xenogeneic
sources.
Decellularization can be achieved using, without limitation, one or a
combination of the following
techniques: highly acidic solutions, highly basic solutions, hypertonic
solutions, hypotonic
solutions, alcohols, detergents, and physical methods such as pressure and
cyclic freeze-thaw.
Such material may also be subjected to a microbial/viral load reduction (e.g.,
sterilization)
step which can be achieved using, without limitation, one or a combination of
the following
techniques: chemical sterilants, contact with ethylene oxide, gamma
irradiation, electron beam
irradiation, contact with supercritical carbon dioxide, exposure to heat,
contact with highly acidic
solutions, or contact with highly basic solutions. For example, without
limitation, one or more
sterilization steps, which may be performed before or after any of the method
steps described
herein, but which are expected to be most effective when performed after as
many such steps as is
practical, such as without limitation, after all other processing steps have
been completed. In some
embodiments, no chemical sterilants are used, but rather only by application
of one or more of
34
CA 03138899 2021-11-01
WO 2020/227601
PCT/US2020/032022
electron beam, gamma radiation, or heat, to the tissue derived porous
matrices. In some
embodiments, both chemical sterilants and other techniques are applied.
The method for making the tissue derived porous matrices may, optionally, also
comprise
the step of forming a plurality of pores (i.e., a porous structure), or
modifying a plurality of existing
pores, in the matrices by one or a combination of pore forming techniques
known now or in the
future. For example, without limitation, pores may be formed or modified in
the tissue derived
porous matrices by one or a combination of the following techniques: freezing
(controlled or
uncontrolled rate); freeze-drying (i.e., lyophilizing) in an open mold or
around a removable lattice-
like structure, with or without mixing at various ratios with an aqueous
solution; porogen leaching;
gas foaming; 3D printing; electrospraying; and air drying around a removable
lattice-like structure.
In some embodiments, cross-linking may be performed on the matrices to
maintain the
stability of the biosponge and to control the resorption rate of the biosponge
once applied to the
wound site, by means known to those in the field, including but not limited to
heat crosslinking,
solution or vapor crosslinking methods with various crosslinkers mentioned
below,
dehydrothermal (heat treatment under vacuum) crosslinking, various photo-
crosslinking methods
including ultra violet (UV) irradiation, electron beam irradiation, gamma
irradiation with or
without riboflavin or ascorbic acid, exposure to glutaraldehyde (GA), exposure
to 1 -ethyl-343-
dimethylaminopropyl] carbodiimide (EDC) with or without N-
hydroxysulfosuccinimide (NHS) in
the presence or not of the amino acid lysine, exposure to genipin or other
naturally derived
crosslinkers, exposure to Grape seed extract mainly composed of
proanthocyanidin (PA), exposure
to acyl azide such as hydrazine or diphenylphosp horylazide (DPPA), exposure
to hexamethylene
diisocyanate (HMDIC).
CA 03138899 2021-11-01
WO 2020/227601
PCT/US2020/032022
In some embodiments, the cross-linking is not uniform and the porous structure
may be
crosslinked so as to obtain a gradient of crosslinking degrees throughout the
structure cross-
section, which produces varying degrees of stability and resorption of the
collagen.
In one embodiment, the biosponge is composed of two or more layers of ECM
sponges of
varying porous degrees that have been chemically/physically bound.
In some embodiments, the biosponge may also have macro-pores which are
transverse
channels of from about 0.5 to about 2.0 millimeters (mm) in diameter, such as
without limitation,
from about 0.5 to about 1.5 mm and evenly dispersed throughout the surface of
the sponge, that
can be introduced before or after crosslinking.
EXAMPLES
The following descriptions, flowcharts and tables provide exemplary
embodiments of
methods for making the tissue derived porous matrices from particular
recovered tissue types,
including human placenta and human dermis.
Test Methods for Characterization
The following descriptions provide explanations for each of the test methods
employed to produce
the characterization data and information provided below in the Biosponge
Testing Matrix tables
for each embodiment (i.e., placental and dermal).
Compressive Deflection Force testing (based on ASTM D3574)
1. Measure the height of the sponge.
2. Measure the length and width, or diameter of the sponge.
36
CA 03138899 2021-11-01
WO 2020/227601
PCT/US2020/032022
3. Slowly add Simulated Chronic Would Fluid (sCWF) [50% TrisHC1 titrated to pH
8-8.5 +
50% FBS, 2% w/v peptone + 40mg/L elastase], until the sponge is completely wet
and
saturated, when excess fluid begins to seep out of sponge.
4. Place the saturated sponge onto the testing stage.
5. Calculate 50% of the height of the sponge based on previous measurements.
6. Using a force gauge with a flat test plate, move the plate downward until
the clearance
between the testing stage and the test plate is equal to the calculated 50%
height,
compressing the sponge to 50% of its original height.
7. Note the peak force (in N) recorded by the force gauge during the test.
8. Divide the peak force by the surface area of the sponge's top face, then
convert from units
of N/mm2 to units of kPa per known conversion values.
Unconfined Compression Testing
1. Samples were cut to a uniform size of 1.5 x 1.5 x 2 cm.
2. Samples were rehydrated in PBS for 1 minute.
3. A compression ramp test to 60% strain (12mm) was performed at a strain rate
of 0.1
mm/sec on a test frame (ElectroForce 5500, TA Instruments)
4. Material stress (a) was calculated as load divided by cross-sectional area.
5. Material strain (6) was calculated as change in height divided by initial
height.
6. The elastic compressive modulus (E) was calculated from the slope of the
upper region
of the stress-strain curve.
7. The resilience was calculated as the area under the stress-strain curve
through 60%
strain.
37
CA 03138899 2021-11-01
WO 2020/227601
PCT/US2020/032022
Compressive Stress-Relaxation Testing
1. Samples were cut to a uniform size of 1.5 x 1.5 x 2 cm.
2. Samples were rehydrated in PBS for 1 minute.
3. To simulate the load applied during use with common negative pressure
devices, the
common setting of 125mmHg was converted to a load of 3.6N given the sample
geometry.
4. Using the data from the unconfined compression testing the 3.6N was
converted to a
strain (e) to be applied to each sample.
5. Using the test frame, a displacement ramp was applied to the sample at
4mm/sec until
.
6. The sample was held at this strain for 180 s before unloading at a rate
of 4mm/sec.
7. The sample was allowed some time to fully relax unloaded before applying
the strain
ramp and release in steps 5 and 6 for another iteration.
8. The resulting data was used to model the time-dependent behavior of the
sample
according to the equation a(t) = Ae-th+ B and fitting the coefficients and
time constant
(T) to the experimental data.
Rheological Testing
1. Samples were cut to a uniform size of 1.5 x 1.5 x 2 cm.
2. Samples were rehydrated in PBS or BSA for 1 minute.
3. The shear properties of the samples were measured using a rheometer (Anton
Paar
MCR 301).
38
CA 03138899 2021-11-01
WO 2020/227601
PCT/US2020/032022
4. A 25 mm diameter parallel plate geometry was used to apply shear at a
measurement
height of 8.5 mm.
5. An oscillatory amplitude sweep was performed on each sample at a constant
angular
frequency (0.1% to 100% strain at 1 rad/s and 10 rad/s) to measure shear
stress (a) as
a function of strain (E).
6. Shear modulus (G) was calculated using this data and the equation a = G x
E.
Degradation Testing
1. 1.5 x 1.5 x 2 cm samples were rehydrated in PBS or PBS with BSA at a
concentration
of 1 g/dL albumin (common concentration in wound exudate found in literature).
2. Each samples was placed in a separate 50 mL conical tube and 15 mL of
solution was
added to each.
3. The samples were stored in a static incubator at 37 C for 7 or 14 days.
4. The samples were tested for unconfined compression and rheology as detailed
above.
Fluid Flow Testing
1. Samples were cut to 28 mm diameter to fight tightly into a 60mL syringe
with a 26.72
mm inner diameter.
2. The samples were coated on the edges with super glue and each positioned at
the base
of a syringe.
3. The syringes were places in a syringe pump with tubing leading to a 3-way
stopcock
split between a Dwyer pressure gauge and a beaker with PBS.
4. The syringe pump was used to set flow rates to withdraw fluid through the
sample.
39
CA 03138899 2021-11-01
WO 2020/227601
PCT/US2020/032022
5. Flow rates of 30, 40, 50, 60, 70 mL/min were set and the pressure was
recorded at each
rate once stabilized.
6. The sample resistance was calculated as the slope of the best fit line
of this pressure
and flow data (resistance = change in pressure / change in flow).
Hydration Testing
1. Samples were cut to a uniform size of 1.5 x 1.5 x 2 cm.
2. Dry mass was recorded for each samples (Ma)
3. Samples were hydrated by being placed into individual 50mL conical tubes
with 15mL
of PBS and kept at 37 C for 24 hours.
4. Samples were removed from the conical tubes and hydrated masses were
recorded
(Mw).
5. Hydration ratio was calculated as mass change percentage = (Mw ¨ Ma) / Md X
100.
Fluid Flow-through testing (Simulated NPWT System)
1. Simulated NPWT System setup:
a. Prepare sCWF, optionally without elastase as the test is of a short
duration.
b. Prepare a test chamber comprising a resealable pouch with ports for
inlet/outlet/pressure measurement (see Figure 3).
c. Connect a vacuum pump to the side port of an aspirator flask. Connect a
suction
pad/tubing to the top port of an aspirator flask with a stopper to seal (See
Figure 4).
d. Place the suction pad onto the outlet port and seal with drape.
e. Connect a vacuum gauge to the pressure measurement port.
CA 03138899 2021-11-01
WO 2020/227601
PCT/US2020/032022
f. Connect tubing with a valve to the inlet port.
g. Turn on the pump and adjust vacuum to desired level (-50mmHg gauge
pressure)
using the pump gauge, ensure no leaks are in the system, then turn off
h. Open the test chamber and place a pre-wetted test sponge between the outlet
and
measurement ports.
i. Reseal the test chamber.
2. Turn on the vacuum with the inlet valve closed and allow the pouch to
completely collapse
under vacuum.
3. Place inlet tubing into a container containing 200mL of sCWF, then open the
inlet valve.
a. If sCWF is not flowing into the inlet tubing, adjust vacuum level on pump
until
liquid begins to flow.
4. Record the time needed to pull 200mL of sCWF through the simulated NPWT
system.
a. Using the 200mL volume and time, calculate an average volume/min flow rate
5. Optionally, after fluid has been pulled through the system, measure the
amount of sCWF
collected in the aspirator flask.
Delivery of negative pressure (Simulated NPWT System)
1. During Fluid Flow-through testing with sponge inserted but inlet still
closed, record the
vacuum measured by the gauge.
2. During Fluid Flow-through testing with sponge inserted and inlet opened,
record the
vacuum measured by the gauge.
Durability ¨ qualitative (cutting)
41
CA 03138899 2021-11-01
WO 2020/227601
PCT/US2020/032022
1. Cut a dry sponge using surgical scissors and observe any breakage or
cracking
2. Cut a wetted sponge using surgical scissors and observe any breakage or
cracking.
Durability ¨ qualitative (high vacuum)
1. After Fluid flow-through testing is completed, increase vacuum level on the
pump to -
200mmHg and allow to pull more sCWF through the line.
2. After 1 minute, turn off the pump and remove the sponge.
3. Visually inspect the collected fluid in the aspirator flask for
presence of tissue particulates.
4. Visually inspect the sponge for breakage or cracking.
Resorption ¨ simulated chronic wound fluid enzyme degradation
1. Place sponges saturated with sCWF into small sealable containers to
simulate sponges
being exposed to chronic wound fluid enzyme degradation.
2. For worst case, add additional sCWF and completely immerse sponge.
3. Seal containers and place into a water bath set to 37 C.
4. Keep saturated and/or immersed sponges in the water bath for 5 days.
5. Remove containers from the water bath.
6. Open the containers and remove the sponges.
7. Visually inspect the fluid remaining in the container for presence
of tissue particulates.
8. Test the saturated and/or immersed sponges per Fluid Flow Through test
method.
Pore Size - Scanning Electron Microscopy (SEM)
1. Cut samples from a sponge to generate vertical and horizontal cross-
sections.
42
CA 03138899 2021-11-01
WO 2020/227601
PCT/US2020/032022
2. Place double-sided carbon tape onto SEM specimen pin stubs.
3. Place each sample onto the expose carbon tape of a stub and allow the
sample to come into
full adhesive contact.
4. Use a sputter coater [Leica EM ACE600 Sputter Coater] to coat each sample
with
approximately 5nm of iridium deposition, optionally with sputtering sequences
including
0-45 tilt to ensure full specimen coverage.
5. Image the specimens using a scanning electron microscope [XL30 FEG-SEM].
6. Analyze using ImageJ software:
a. Set Scale
b. Apply Auto Threshold
c. Measure Particles (500um2 or larger)
d. Summarize (Feret Mean)
Porosity (liquid displacement)
1. Add 50mL absolute ethanol (Vi) into a wide mouth 100mL graduated cylinder,
ensuring
the cylinder is wide enough to accommodate sponge samples.
2. Place a foam test sample into the graduated cylinder such that it is
submerged in the
ethanol.
3. Pull a vacuum in the graduated cylinder to draw out air bubbles in the
sponge and ensure
complete wetting of internal pores.
4. Measure the volume of the ethanol with the sample submerged (V2).
5. Remove the sponge sample carefully, without compressing the sample to avoid
expelling
liquid from the sample.
43
CA 03138899 2021-11-01
WO 2020/227601
PCT/US2020/032022
6. Measure the remaining volume of ethanol in the graduated cylinder (V3).
7. Calculate porosity of the sample by the formula (Vi-V3)/(V2-V3).
Matrix Composition ¨ biological factors
1. Cut samples from a sponge.
2. Send sponge sample to third party histology lab for embedding, section, and
then
histological or immunohistochemical (IHC) staining:
a. H&E staining
b. Glycosaminoglycans (GAGs) via Safranin 0 staining
c. Collagen III via IHC
d. Collagen IV via IHC
e. Hyaluronic Acid (HA) via IHC
f. PDGF-bb via IHC
g. VEGF via ITIC
3. Visually evaluate slides for presence of positive staining as compared to
positive and
negative control slides.
Residual Moisture Content determined per USP<731> loss on drying
1. 1-2 grams of sponge was sent for analysis.
2. Oven is preheated to 105 C 2C.
3. Place sample dish in oven for 30 minutes, place in dessicator to cool.
4. Place dish on balance and weigh. Tare balance.
5. Place sample in dish and weigh.
44
CA 03138899 2021-11-01
WO 2020/227601
PCT/US2020/032022
6. Place dish with sample into heated oven for 24 hours.
7. After 24 hours, place dishes in dessicator to cool.
8. Place on balance and weigh.
9. Percent residual moisture (%) is calculated as (Initial weight-Dry sample
weight)/Initial
weight x 100.
Pre-clinical Efficacy in an Animal Model
A pre-clinical study intended to evaluate the efficacy of the biosponge in an
animal model will be
performed and is described below, followed by listings of study evaluation
parameters and scales.
The study will be conducted in a porcine model to assess wound bed granulation
and tissue
incorporation of the biosponge into the wound bed. Healing will be compared to
currently available
synthetic foam for NPWT as a control. It is expected that the results of this
study will show faster
and/or more thorough granulation tissue formation in the biosponge test group
versus the synthetic
foam control.
Protocol Design Overview:
= One (1) pig will be used in this study which will run for a total of
seven (7) days.
= Experimental procedure
o Sixteen (16), full-thickness, 3cm x 3cm square wounds will be created
freehand on
each pig using a scalpel blade and forceps; eight (8) on each side of the pig
o Wounds will NOT be infected in this study (possible perioperative
antibiotic use)
o Wound Dressings:
= Row A: Control- Synthetic NPWT foam dressing (KCI GranuFoam)
CA 03138899 2021-11-01
WO 2020/227601
PCT/US2020/032022
= Foam material and drape/suction pad will be replaced at each dressing
change
= Row B: Treatment 1 ¨ Biosponge Formulation #1
= drape/suction pad only will be replaced at each dressing change
= Row C: Treatment 2 ¨ Biosponge Formulation #2
= drape/suction pad only will be replaced at each dressing change
= Row D: Treatment 3 ¨ Currently available meshed acellular dermal matrix
in
conjunction with synthetic NPWT foam dressing
= drape/suction pad only will be replaced at each dressing change
= N=4 data points per dressing application
o Appropriate ports will be applied over the foam dressings and a commercially
available
NPWT device will be connected.
= The device will be turned on and ran on the -125mmHg continuous setting
throughout the study.
o Pig will be sacrificed on Day 7
= Assessment parameters include:
o Digital caliper measurements for wound size and depth: DO, D2, D4, and D7
o Digital photographs will be taken on: DO, D2, D4, and D7
o Histology
= Each wound will be excised with lcm surrounding normal tissue
circumferentially
and deep to the wound and fixed in 10% neutral buffered formalin.
= Samples will be sent to a histopathology laboratory for trimming,
embedding,
sectioning, staining, and histopathology/histomorphometry evaluation.
46
CA 03138899 2021-11-01
WO 2020/227601
PCT/US2020/032022
o Histopathology:
= H&E:
= Adverse tissue reaction scoring (rubric below)
= Collagen maturation scoring (semi-quantitative per rubric)
o Histomorphometry:
= H&E:
= Granulation tissue thickness (measured at 3 evenly spaced intervals
across
wound bed)
= Granulation tissue ingrowth into dressing material (if applicable)
= CD31:
= Vascular density quantification within Region of interest (ROT)
Typical Histopathology Evaluation Parameters:
= Overall inflammation (wound bed)
= Overall inflammation (surrounding residual test 0 = Absent
article or control article material), when applicable
= Edema/seroma
formation 1 = Minimal
= Serocellular debris at the wound surface
= Hemorrhage
2 = Mild
= Necrosis within wound bed
3 = Moderate
= Abscess formation (superficial wound bed)
= Granuloma
formation 4 = Marked/Severe
= Microgranuloma formation
= Mineralization
Inflammatory Response: 0 = Absent
= Neutrophils 1 = Rare,
1-5/hpf (MNGC = 1-2/hpf)
= Eosinophils 2 = 6-
10/hpf (MNGC = 3-5/hpf)
47
CA 03138899 2021-11-01
WO 2020/227601 PCT/US2020/032022
= Lymphocytes 3 = Moderate,
heavy infiltrates
= Plasma Cells 4 = Packed
(MNGC = sheets)
=
Macrophages (/hpf = per high-powered (400x) field)
= Multinucleated Giant Cells (MNGC)
0 = No collagen deposition.
1 = Scanty collagen deposition as a loose, poorly
organized stroma.
2 = More notable collagen deposition than Score
1, with the majority of the stroma still loose and
Nature of newly deposited collagen:
poorly organized with collagen fibers
predominately oriented
parallel and
= Collagen maturation of
superficial wound bed perpendicular to the skin surface.
=
Collagen maturation of deep wound bed 3 = More notable collagen maturation
than Score
2, with the majority of the stroma appearing
dense and organized with collagen fibers
oriented parallel to the skin surface.
4 = More notable collagen maturation than Score
3, with majority of stroma having the
appearance of native dermal collagen.
0 = No ingrowth of epithelium beyond wound edge.
1 = Less than 1 mm of ingrowth of epithelium
beyond wound edge on one or both sides of the
wound.
Epithelialization at the wound edges 2 = Greater than 1 mm of ingrowth of
epithelium
beyond wound edges on both sides of the
wound but not fully re-epithelialized.
3 = Surface of wound completely covered by
epithelium.
0 = No granulation tissue filling of wound bed.
1 = ¨1% ¨ 25% of wound bed filled.
2 = ¨26% - 50% of wound bed filled.
Granulation tissue filling of wound bed 3 = ¨51% - 75% of wound bed filled.
4 = ¨76% - 100% of wound bed filled.
=> 100% of wound bed filled (excessive
granulation tissue).
0 = Absent.
1 = Very few small vessels scattered throughout the
wound bed.
Vascularization within wound bed
2 = Numerous blood vessels in few areas with
mostly low numbers of blood vessels
throughout the wound bed.
48
CA 03138899 2021-11-01
WO 2020/227601
PCT/US2020/032022
3 = Moderate, numerous blood vessels interspersed
throughout portions of the wound bed with
areas of lower vascular density interspersed
throughout.
4 = Marked, numerous blood vessels interspersed
throughout the wound bed.
Other Findings:
P = Present
= Foreign debris
A = Absent
= Bacteria
When present, the fibrous capsule will be
Fibrous Capsule measured in three random
locations per slide
using an ocular micrometer.
Example 1: Placenta Biosponge Prepared from Recovered Human Placenta Tissue
A placenta biosponge was prepared from human placenta tissue according to the
general method
shown in Figure 5, with the specific parameters performed described below.
Initial processing, up through decellularization:
A placenta disk and optionally also the umbilical cord and amnion/chorion
membranes, were first
cleaned in water. The tissue was then subdivided and blended with a hypertonic
solution to create
a tissue/hypertonic solution mixture. The mixture was agitated to
decellularize the tissue
components. The mixture was then centrifuged and then resuspended and agitated
in water to
remove the hypertonic solution.
1. A placenta was obtained, comprising the disk, the umbilical cord and
membranes in
addition.
2. The tissue was soaked and massaged in room temperature water to help expel
excess blood
and remove blood clots.
3. The tissue was then cut into smaller pieces using a scalpel.
49
CA 03138899 2021-11-01
WO 2020/227601
PCT/US2020/032022
4. Avoiding transfer of excess liquid, the tissue pieces were combined with 1L
1M NaCl
solution in a heavy duty blender [Waring].
5. The tissue mixture was blended for approximately 1 minute on High speed,
two times.
6. The tissue mixture was then transferred into a 2L flask and agitated on an
orbital shaker at
90 to 150 rpm for approximately 2 hours.
7. The tissue mixture was transferred into centrifuge bottles and centrifuged
at 4600RPM for
minutes, then the supernatant was poured off.
8. A total of 1L of water was combined with the remaining tissue pellets
and transferred into
a 2L flask and agitated on an orbital shaker at 90rpm for approximately 5
minutes.
10
9. The tissue mixture was transferred into centrifuge bottles and centrifuged
at 4600RPM for
5 minutes, then the supernatant was poured off.
10. A total of 1L of water was combined with the remaining tissue pellets and
transferred into
a 2L flask and agitated on an orbital shaker at 90rpm for approximately 5
minutes.
11. The tissue mixture was transferred into centrifuge bottles and centrifuged
[at 4600RPM for
10 minutes], then the supernatant poured off.
12. The tissue pellets were recovered and frozen at -20C for staging prior to
disinfection.
Disinfection (i.e., reducing microbial load):
The decellularized tissue was blended with a peracetic acid-based disinfection
solution and then
agitated to disinfect the tissue. The tissue mixture was subjected to a series
of centrifugation steps,
each followed by agitation in water, to remove the disinfection solution. The
remaining tissue was
combined with water in a variety of potential ratios to create a tissue
mixture, which was then
frozen prior to lyophilization.
CA 03138899 2021-11-01
WO 2020/227601
PCT/US2020/032022
1. The tissue was combined with 1L of peracetic acid based disinfection
solution in a heavy
duty blender (Waring).
2. The tissue mixture was blended for approximately 1 minute on High speed.
3. The tissue mixture was then transferred into a 2L flask and agitated on an
orbital shaker at
90rpm for approximately 2 hours.
4. The tissue mixture was transferred into centrifuge bottles and centrifuged
at 4600RPM for
minutes, then the supernatant poured off for disposal.
5. A total of 1L of water was combined with the remaining tissue pellets in a
heavy duty
blender and blended for approximately 1 minute on High speed.
10 6. Tissue was subjected to multiple (8) rinses with agitation sufficient
to remove PAA
residuals. Tissue was subjected to a 1-minute blending step on High after the
7th rinse, and
before the final rinse.
7. The tissue mixture was transferred into centrifuge bottles and centrifuged
at 4600RPM for
10 minutes, then the supernatant poured off
8. The tissue pellets were recovered and stirred to make a more homogenous
mixture, and
then weighed in a tared container. This was considered the baseline "100%
tissue mixture".
9. Water was combined with the tissue mixture to obtain a 50% tissue mixture.
10. The final tissue mixture was then aliquotted into suitable containers for
lyophilization,
consisting of 2 6-well plates and a small aluminum cup.
Drying / Lyophilization:
The tissue mixture was dried by lyophilizing: tissue was placed into a
lyophilizer and the
lyophilization cycle provided in the chart below was run to obtain a dried
tissue form.
51
CA 03138899 2021-11-01
WO 2020/227601
PCT/US2020/032022
Lyophilization Cycle ¨ Placental Biosponge Recipe
Temperature Time
Recipe Phase ( C) (min) Vacuum (mTorr)
Ramp/Hold
Thermal Treatment
Step 1 -40 240 Hold
Freeze Temperature -40 Hold
Additional Freeze Time 30
Condenser Set Point -40
Vacuum Set Point 600
Drying Phase
Step 1 -5 5,760 600 Hold
Secondary Drying Phase
Post Heat Step 24 720 600 Hold
Crosslinking:
A chemical crosslinking solution was prepared (for example, see below). The
solution was added
to the dried tissue form and allowed to crosslink the tissue. After
crosslinking, the solution was
removed and the tissue was rinsed in water to remove residual crosslinking
solution.
1. Preparation of crosslinking solution.
a. 60 mM 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (aka EDC) and 24 mM n-
hydroxysuccinimide (aka NHS) in water.
2. The crosslinking solution was slowly added to the contained lyophilized
tissue, avoiding
dispensing directly onto the tissue, until tissue was completely immersed.
Wetting of the
tissue by the solution was ensured, while avoiding pressing down to avoid
collapsing the
yet-uncrosslinked structure.
3. Crosslinking was allowed for 60 minutes at room temperature.
52
CA 03138899 2021-11-01
WO 2020/227601 PCT/US2020/032022
4. Excess crosslinking solution was removed and tissue was transferred into a
container with
an excess of water, and rinsed for 15 minutes. This was repeated for a total
of 4 water
rinses.
5. The rinsed tissue retained its shape and its ability to absorb liquid, as a
sponge.
Final drying / lyophilization step (optional step):
The crosslinked sponges were lyophilized again to yield dry sponges suitable
for packaging and
long term storage.
1. The sponges were placed into suitable containers and lyophilized again
[using same
lyophilizing cycle as provided in the chart above].
2. Crosslinked and lyophilized sponges were packaged as appropriate.
The details of the foregoing experiment which produced a placenta biosponge
are set forth in the
following Tables 1A and 1B, with the results and product characteristics
reported in the "Results"
column of Table 1B.
53
Table 1A ¨ Placenta Testing Matrix
0
o
o
Metric Specification Method
Reference points -R,--
t..,
-4
c.,
=
CFD ASTM D3574-08
Option 1: Compression deflection
Peak compression (N) at 50% thickness Current sponge values closer to 2-
Mechanical properties force
using a 2inch diameter compression
4 kPa
2-4 kPa, 2-10 kPa (range)
platen
Option 2: Compressive strength
P
Mechanical properties
o
comparable to current NPWT Compressive strength
ASTM D1621 ,
(cont'd)
00
vi black foam or white foam
3
r.,
r.,
,
,
1) "Low to moderate amounts of
,
,
,
exudate" = 37.5m1/day
o
At least 200cc of SWF delivered at
,
2) KCI algorithm for SNAP single
once, and delivered in increments
use system = ¨26ml/day
of 25 ml is able to be evacuated at
(<180m1/week)
vacuum pressure ranges of 50,
3) Novopore 510k
Fluid Flow through 125, 200 mmHg (KCI). Worst case: In vitro vac
system
4) KCI sponge + collagen dressing
50mmHg
acceptance criteria
5) NPWT with instillation can be 1-d
n
To also monitor: % of fluid being
exposed to up to 100cc of
drawn out
instillation fluid (saline or other)
cp
o
for 15 minute cycles
t,.)
o
-a-,
t..)
=
t..)
t..)
Table lA ¨ Placenta Testing Matrix (continued)
o
Metric Specification Method
Reference points t..,
=
t..,
=
-R,--
t..,
-4
25 ml fluid drawn through within
o
o
1-
30 seconds at 0, 24, 48, 72 hrs
(NovoPore 510K compared to KCI
Granufoam) - for info only for
comparison against NPWT black
foam or white foam
1) Does not crack when cut with
scissors
P
Simulated handling
Normal handling during clinical
Durability - qualitative 2) Does not crack or disintegrate
.
In vitro vac system
use ,
when wet and exposed to vacuum
.3
.3
vi @ 200mmHg
.
N)
.
N)
,
,
48-72 hrs change is standard for
,
,
,
VAC therapies today, 5 days
0
,
Enzymatic degradation in SWF -
Stable for at least 5 days when eliminates a dressing change
submersion in SWF @ 37C for 0, 24,
Resorption exposed to SWF, "Stable" = meets
(Nichols)
48, 72, 96, 120 hrs hours and then
fluid flow through specs
7 days is the expiration of single
exposure to vacuum system
use NPWT systems (SNAP therapy
KCI)
1-d
Loh et al. 2013 cites, "Artel et al.
n
,-i
2011 showed that larger pore
Pore size Approximately 160-270um SEM
sizes of approximately 160 to cp
o
270 p.m facilitated angiogenesis
t,.)
o
throughout scaffold"
t..)
=
t..)
t..)
Table lA - Placenta Testing Matrix (continued)
o
Metric Specification Method
Reference points t..,
=
t..,
=
-R,--
t..,
-4
o
Percent porosity - no spec, just
o
Porosity info info only to provide comparison to Liquid
Displacement
NPWT black foam
Contains factors supporting
granulation tissue formation,
Matrix Composition I HC
angiogenesis, and may contain
anti-inflammatory factors
P
,
.3
.3
r.,
r.,
'7
,
,
,
,
1-d
n
,-i
cp
t..)
=
t..)
=
-a,
t..)
=
t..)
t..)
Table 1B ¨ Placenta Testing Matrix
o
t..,
Metric References Test article description
Results =
t..,
=
-R,--
t..,
-4
At 50% compression and saturated with liquid:
o
o
(1) Lessing et al., NPWT with Controlled Saline Instillation,
1¨
1) Saturated sample 17.048kPa before,
9.633kPa after 5 days
Wounds 2011: 23(1): pp. 309-
2) Immersed sample 13.721 kPa before,
319
5.415kPa after 5 days
Time 0 (Before 5-day incubation)
With final tissue yield from last
1) Saturated sample: 0.7108g, center height
process step as "100%" tissue
11.64mm, edge heights 9.67,9.92,9.80mm P
mixture, used 50% mixture with
diameters 31.28, 31.19, 31.51mm, peak force .
,
Mechanical properties lyo, with 1hr
crosslinking in 13.14N .3
.3
vi
.
--4 60mM [DC! 24mM NHS in
water 2) Immersed sample 0.7384g, center height .
r.,
.
with 4x 15min water rinses and
11.59mm, edge heights 11.02, 11.14, 11.21 r.,
,
,
relyo after;
mm diameters 31.01, 31.39, 31.69mm, peak ,
,
,
force 10.60N
,
Post 5-day incubation
1) Saturated sample height 9.97mm, diameter
33.91mm, peak force 8.7N
2) Immersed sample height 12.22mm,
diameter 34.63mm, peak force 5.1N
1-d
n
,-i
Mechanical properties
N/A
cp
(cont'd) -
t,.)
o
o
-a,
t..,
=
t..,
t..,
Table 1B ¨ Placenta Testing Matrix (continued)
o
Test article
t..,
Metric References
Results =
description
t..,
=
-R,--
t..,
-4
(2) FDA 510k K161432
Flow rates to pull 200mL of
simulated wound fluid o
o
(3) Acelity NPWT algorithm
(high pH buffer with high protein
and protease 1¨
webinar/brochure
content) all much higher than reported clinical
(4) FDA 510k K132936 exudate levels
(5) Westmoreland et al., An in vitro
evaluation of a collagen/ORC/silver wound
1) TO at 95mmHg took 47min (4.26mL/min)
Fluid Flow through -
dressing under NPWT, SAWC Fall 2017
Both saturated and immersed sample able to pull
(6) Dettmers et al., Negative Pressure Wound through 200cc of SWF after 5
days in simulated
Therapy With Instillation and Dwell Time
CWF. P
Used to Treat Infected Orthopedic Implants:
2) Saturated sample took 18min 355ec o
,
A 4-patient Case Series, 2016, 62(9): pp. 30-
(10.76mL/min)
.3
.3
oe 40
3) Immersed sample took 76min (2.63mL/min) -
r.,
r.,
,
, , spec equivalent to 50mL/min see data above - ,
,
,
,
1) can be cut wet, when cut dry generates
crumbs/flakes and can crack
2.1) TO sample no crack after pulling 200mmHg
Durability ¨ qualitative
2.2) Saturated sample no crack after pulling
200m m Hg
2.3) Immersed sample w/ superficial crack after
1-d
n
200mmHg but no loss of structural integrity, no
tissue pulled into line
cp
o
o
-a-,
t..,
=
t..,
t..,
Table 1B - Placenta Testing Matrix (continued)
0
t..)
Metric References Test article description
Results =
t..,
=
-R,--
t..,
-4
o
(9) Co-Inventor discussions Both saturated and immersed sample were
1¨,
Resorption
2017
stable, no tissue pulled into line
(7) Loh UL et al., Three-
dimensional scaffolds for
Crosslinked, dry, pore size via SEM imaging and
tissue engineering
Pore size
ImageJ analysis: 158.59um avg Feret diameter,
applications: role of porosity
range 37.82-1482.81um, SD 19.266um
and pore size. Tissue Eng Part
P
B Rev. 2013;19(6):485-502.
,-,
.3
.3
o .
,,,
(8) Ho et al., A comparison of
c,
N)
Range based on limited resolution of
,
micro CT with other
,-,
,-,
, graduation markings:
c,
techniques used in the
,-,
Porosity
Granufoam: 88.9%-100%
characerization of scaffolds,
WHITEFOAM: 92.3%-100%
Biomaterials, 2006 v27,
Biosponge estimated 80%-85.7%
pp1362-1376
High levels of Col IV, ubiquitous Col III and HA.
1-d
Matrix Composition
Low levels of GAGs. No PDGFb noted and n
,-i
traces of VEGF in 1 of 3 donors
cp
o
o
-a-,
t..)
=
t..)
t..)
Example 2: Dermis Biosponge Prepared from Recovered Human Dermis Tissue
A dermis biosponge was prepared from human dermis tissue according to the
general method shown in Figure 6, with the specific 0
parameters performed described below.
Initial processing, up through decellularization:
The deep layer of the reticular dermis (deep dermis) was first isolated from
the full thickness dermis. The tissue was cut to smaller pieces
by hand, then blended in a knife mill with a hypertonic solution to create a
mixture. The mixture was agitated to decellularize the tissue
components. The mixture was then blended again in the knife mill and then
centrifuged. The pellet was resuspended in a surfactant
solution and agitated to further decellularize the tissue components. The
tissue was then subjected to a series of agitations in water to
remove the surfactant solution.
1. The deep dermis was isolated from the full thickness dermis.
2. The deep dermis was frozen at -70 C until further processing.
3. The deep dermis was thawed at room temperature.
4. The deep dermis was cut to smaller pieces using scissors or a rolling blade
cutter.
5. The cut tissue was added to the container of the knife mill (GM200) with
1M NaCl at a ratio of 1:4 tissue to solution by weight.
6. The tissue mixture was blended for 10 seconds at 7000 rpm, then 20 seconds
for 10000 rpm, then 20 seconds for 10000 rpm.
7. The tissue mixture was transferred to a 2L flask and agitated on an orbital
shaker at 150 rpm for 12-24 hours.
8. The tissue mixture was poured directly into the container of the knife
mill.
9. The tissue mixture was blended again using the previously mentioned
parameters.
10. The tissue mixture was centrifuged.
0
11. The pelleted tissue was resuspended in 0.1% Triton X solution.
12. The tissue mixture was transferred to a 2L flask and agitated on an
orbital shaker at 150 rpm for 24-28 hours.
13. The tissue was separated from the 0.1% Triton X solution using a
centrifuge or sieve.
14. The tissue was added to water for rinsing and agitated on an orbital
shaker at 150 rpm for 5 minutes.
15. The tissue was separated from the water using a centrifuge or sieve.
16. This was repeated for a total of eight water rinses.
17. The tissue was frozen at -70 C (or -20 C or -80 C) until further
processing.
Disinfection (i.e., reducing microbial load):
The decellularized tissue is thawed and agitated with a peracetic acid-based
disinfection solution to disinfect the tissue. The tissue
mixture is then blended in the knife mill, followed by four neutralization
rinses in lx DPBS solution, with centrifugation after each.
The remaining tissue is combined with water in a variety of potential ratios
to create a tissue mixture, which is then transferred to a mold
prior to lyophilization.
11. The tissue was thawed at room temperature.
12. The tissue was added to a 2L flask with 1L of peracetic acid based
disinfection solution.
13. The tissue mixture was agitated on an orbital shaker at 150 rpm for 2-4
hours.
14. The tissue mixture was added directly to the container of the knife mill
and blended using the previously mentioned parameters. 0
15. The tissue mixture was centrifuged to remove the disinfection solution and
to produce a pellet.
16. The pellet was resuspended in lx DPBS in a 2L flask and agitated on an
orbital shaker at 150 rpm for 5-20 min.
17. The tissue mixture was centrifuged to remove the 1X DPBS.
18. This was repeated for a total of four lx DPBS neutralization rinses.
19. The tissue was mixed by hand with water to a ratio of 25:75 tissue to
water by weight.
20. The tissue mixture was transferred to a mold to create the desired shape.
Drying / Lyophilization:
The tissue mixture was dried by lyophilizing: the tissue in the mold was
placed into a lyophilizer and the following lyophilization cycle
was run to obtain a dried tissue form (sponge)
1. The lyophilization parameters used were:
a. Ramp to -40 C at 1 C/min
b. Primary drying at -5 C or less for more than 48 hours
c. Secondary drying at 25 C for at least 8 hours
Crosslinking and final drying/lyophilization:
Cross-linking and final lyophilization was performed as was described in the
cross-linking section of Example 1. 0
t..)
o
t..)
o
t..)
-4
o
The details of the foregoing experiment which produced a dermal biosponge are
set forth in the following Tables 2A and 2B, with the
results and product characteristics reported in the "Results" column of Table
2B.
P
.
2
o,
,,
N)
'7
,
00
n
,-i
cp
t..)
o
t..)
o
O-
,...)
t..)
o
t..)
t..)
Table 2A ¨ Dermis Testing Matrix
o
Metric Specification Method
Reference points t..,
=
t..,
=
-R,--
t..,
-4
o
CFD ASTM D3574-08
o
Option 1: Compression deflection Peak compression
compression (N) at 50% thickness Current sponge values closer to 2-
Mechanical properties force
using a 2inch diameter compression
4 kPa
2-4 kPa, 2-10 kPa (range)
platen
Option 2: Compressive strength
Mechanical properties
(cont'd) comparable to current NPWT Compressive
strength ASTM D1621
black foam or white foam
P
.
,
1) "Low to moderate amounts of
.3
.3
o .
4=,
exudate" = 37.5m1/day .
N)
At least 200cc of SWF delivered at
2) KCI algorithm for SNAP single 0
N)
,
,
once, and delivered in increments
use system = ¨26ml/day ,
,
,
of 25 ml is able to be evacuated at
(<180ml/week) 0
,
vacuum pressure ranges of 50,
3) Novopore 510k
Fluid Flow through In vitro vac
system
125, 200 mmHg (KCI). Worst case:
4) KCI sponge + collagen dressing
50mmHg
acceptance criteria
To also monitor: % of fluid being
5) NPWT with instillation can be
drawn out
exposed to up to 100cc of
instillation fluid (saline or other)
1-d
for 15 minute cycles
n
,-i
cp
t..)
=
t..)
=
-a-,
t..)
=
t..)
t..)
Table 2A - Dermis Testing Matrix (continued)
o
Metric Specification Method
Reference points t..,
=
t..,
=
-R,--
t..,
-4
o
25 ml fluid drawn through within
1-
30 seconds at 0, 24, 48, 72 hrs
Fluid Flow through (NovoPore 510K compared to KCI
(continued) Granufoam) - for info only for
comparison against NPWT black
foam or white foam
1) Does not crack when cut with
P
.
scissors
,
Durability ¨ qualitative 2) Does not crack or disintegrate Simulated
handling Normal handling during clinical .3
.3
o .
vi when wet and exposed to vacuum In vitro vac
system use .
r.,
@ 200mmHg
"
FA
I
FA
FA
I
0
FA
48-72 hrs change is standard for
VAC therapies today, 5 days
Enzymatic degradation in SWF -
Stable for at least 5 days when eliminates a dressing change
submersion in SWF @ 37C for 0, 24,
Resorption exposed to SWF, "Stable" = meets
(Nichols)
48, 72, 96, 120 hrs hours and then
fluid flow through specs exposure to
vacuum system 7 days is the expiration of single
use NPWT systems (SNAP therapy
KC I)
1-d
n
,-i
At least 100um, mean target
"Vascularization of constructs
cp
Pore size
closer to 300-400um SEM
necessitates pores greater than w
=
300 p.m"
w
o
-a,
t..)
=
t..)
t..)
Table 2B ¨ Dermis Testing Matrix
Metric References Test article description
Results
With final tissue yield from last
(1) Lessing et al., NPWT with process step as "100%" tissue
Controlled Saline Instillation, mixture. Time 0 measurement:
Time 0: 4.24 kPa
Mechanical properties
Wounds 2011: 23(1): pp. 309- 1.5cm thick
Time 5days: 2.66 kPa
319 30:70 tissue:water wet weight
1 hour xlink with EDC-NHS
Mechanical properties
N/A
(cont'd)
(2) FDA 510k K161432
(3) Acelity NPWT algorithm
webinar/brochure
(4) FDA 510k K132936
(5) Westmoreland et al., An
in vitro evaluation of a
Time 0: At 100mmHg, 175 ml (200cc but 25 ml
collagen/ORC/silver wound stuck
in system) took 17min145ec5 (10.16
dressing under NPWT, SAWC
ml/min)
Fluid Flow through
Fall 2017
(6) Dettmers et al., Negative
Time 5 days: At 100 mmHg, 57 ml (80cc but 23
Pressure Wound Therapy
ml stuck in system) took 5 mins (11.4m1/min)
With Instillation and Dwell
1-d
Time Used to Treat Infected
Orthopedic Implants: A 4-
patient Case Series, 2016,
62(9): pp. 30-40
Table 2B - Dermis Testing Matrix (continued)
0
t..)
Metric References Test article description
Results =
t..,
=
-R,--
t..,
-4
see above o,
o
,-,
1) can be cut wet, can be cut dry with scalpel
recommended
Durability ¨ qualitative
2) no cracking when pulled at 200 mmHg
2.1) Time 5 days in SWF: no cracking when
pulled at 200 mmHg
Resorption
(9) Co-Inventor discussions
Time 0: Stable, no tissue through line
P
2017
Time 5 days: Stable, no tissue through line
.
,
.3
.3
--4
.
(7) Loh UL et al., Three-
.
N)
,
, dimensional scaffolds for
,
Crosslinked, dry pore size by SEM imaging and
,
,
tissue engineering
.
Pore size
ImageJ analysis: 149.25+/-8.49 avg Ferret
,
applications: role of porosity
diameter, min 85.28
and pore size. Tissue Eng Part
B Rev. 2013;19(6):485-502.
1-d
n
,-i
cp
t..)
=
t..)
=
-a,
t..)
=
t..)
t..)
Example 3: Dermal Biosponge Characterization
Another dermis biosponge was prepared from human dermis tissue according to
the general method shown in Figure 6. The details of 0
this experiment which produced another dermal biosponge are set forth in the
following Tables 3A and 3B, with the results and product
characteristics reported in the "Results" column of Table 3B.
In particular, it is noted that for this Example 3, the tissue derived porous
matrices were produced from dermis tissue using:
- a ratio of tissue to NaCl solution of 1:8 (by weight), rather than 1:4 as
in Example 2;
- a 30:70 tissue to water dilution, rather than 25:75 as in Example 2; and
- 2 hour stabilization (crosslinking) in 6 mM EDC / 2.4 nM NHS
crosslinking solution, rather than 30 minutes in 60 mM EDC
cio
/ 24 mM NHS as in Example 2.
Table 3A - Dermis Testing Matrix
o
Metric Specification Method
t..,
=
t..,
=
-R,--
t..,
-4
o
Unconfined
Comparable to current NPWT o
Unconfined Compression Testing Compression black black foam or white foam
Comparable to current NPWT
Stress-Relaxation Compressive Stress-Relaxation Testing
black foam or white foam
Comparable to current NPWT
Rheology Rheological
Testing
black foam or white foam
P
.
,
.3
.3
vD Comparable to current NPWT
.
Fluid Flow through Fluid Flow Testing
(using syringe pump)
black foam or white foam
.
N)
'7
,
,
,
Degradation Testing - Storage for 7 or
.
,
14 days in BSA at 37C then
Resorption .. Stable after exposure to BSA
compressive and rheological testing as
above
Comparable to current NPWT Hydration Testing
(Percent mass
Hydration
black foam or white foam change after
storage in PBS)
1-d
n
,-i
cp
t..)
=
t..)
=
-a,
t..)
=
t..)
t..)
Table 3B ¨ Dermis Testing Matrix
o
t..,
Metric Test article description
Results =
t..,
=
-R,--
t..,
-4
Compressive Moduli:
o
o
Biosponge: 32.56 +/- 5.87 kPA
1-
1.5 x 1.5 x 2 cm
GranuFoam: 8.80 kPA
Unconfined Compression
Rehydrated in PBS
Resilience:
Biosponge: 2.44 +/- 0.33 J/m3
GranuFoam: 0.95 J/m3
1.5 x 1.5 x 2 cm Time
constant values (T):
Stress-Relaxation
Rehydrated in PBS Biosponge: T1 =
1.07 +/- 0.34, T2 = 1.07 +/- 0.41
P
Shear Modulus @ 1rad/s (kPa):
o
,
Biosponge: 3.21 +/- 0.94
.3
.3
--4
.
o 1.5 x 1.5 x 2 cm GranuFoam: 3.96 -
Rheology
Rehydrated in PBS Shear Modulus
@ 10rad/s (kPA): N)
,
,
Biosponge: 3.25 +/- 0.88
,
,
,
GranuFoam: 4.69
.
,
Flow Resistance (psi min/L):
Fluid Flow through 28mm diameter samples Biosponge:
6.47 +/- 0.97
GranuFoam: 6.68
1.5 x 1.5 x 2 cm
Resorption See
plots to right
rehydrated in BSA
1-d
n
,-i
Average % Mass Change:
cp
Hydration 1.5 x 1.5 x 2 cm Biosponge:
2157 +/- 136 t,.)
o
GranuFoam: 2413 +/- 199
t,.)
o
-a,
t..,
=
t..,
t..,
CA 03138899 2021-11-01
WO 2020/227601
PCT/US2020/032022
Example 4: Dermis Biosponge Prepared from Recovered Human Dermis Tissue
Still another dermis biosponge was prepared from human dermis tissue according
to the more
detailed method shown in Figure 7, with the specific parameters performed
described below.
Cutting and Decellularization
The deep layer of the reticular dermis (deep dermis) is first isolated from
the full thickness
dermis. The deep dermis may then optionally be frozen at -70 C until further
processing.
The deep dermis is cut to smaller pieces, approximately 2x2cm in size or
smaller, using a
rolling blade cutter. The cut tissue is added to 1M NaCL solution into the
container of a knife mill
(GM300, Retsch). The tissue and solution are blended first at 2500 rpm for 20s
and then
subsequently at 4000 rpm for 2 minutes with 20s intervals. The blended tissue
mixture is then
transferred to flasks and soaked in the 1M NaCl for 12-48 hours on a shaker at
150 rpm. Following
completion of the soak the tissue mixture is transferred to the knife mill and
blended first at
2500rpm for 20s and then subsequently at 4000 rpm for 2 minutes with 20s
intervals. After
blending the tissue mixture is centrifuged at 4600 rpm for 5 minutes and the
supernatant is poured
off The pelleted tissue is added to a 0.1% Triton solution and soaked for 24-
48hrs at 150rpm.
Following the soak, the tissue is separated from the solution using a 90-
1101.tm sieve. The tissue
then goes through a sequence of eight 5 minute water rinses on a shaker at 150
rpm. The tissue is
separated from the water after each rinse using a 90-1101.tm sieve. Upon
completion of the rinses
the tissue is frozen at -70 C until further process.
Disinfection and Start of Lyophilization
The frozen tissue is thawed and excess water is separated from the tissue
using a 90-1101.tm
sieve. The tissue is added to a solution containing peracetic acid, ethanol,
and propylene glycol
71
CA 03138899 2021-11-01
WO 2020/227601
PCT/US2020/032022
and soaked for 2-4 hours on a shaker at 150 rpm. Following completion of the
soak the tissue
mixture is transferred to the knife mill along with 10X DPBS to neutralize the
acid. The tissue
mixture is blended at 4000 rpm for 2 minutes with 20s intervals. Following
blending the tissue
mixture is centrifuged at 4600 rpm for 5 minutes and the supernatant is poured
off. The tissue then
goes through three 5 minute rinses in 1X DPBS on a shaker at 150 rpm, with a
centrifuge step at
4600 rpm for 5 minutes after each rinse to separate the tissue from the
rinsate. Upon completion
of the rinses the tissue is diluted with water to create a tissue slurry (ie.
30:70 tissue to water, w:w).
The tissue slurry is transferred to molds and placed into a lyophilizer. An
appropriate lyophilization
cycle is run to obtain a dried tissue form. The technique for performing
lyophilization is not
particularly limited and may be any technique known now or in the future to
persons of ordinary
skill in the relevant art.
Stabilization and Start of Second Lyophilization
Stabilization is performed as described in the cross-linking section of
Example 1. Upon
completion of crosslinking the tissue is placed back in its molds with water
and placed into a
lyophilizer. The same recipe as previous is run to obtain a dried final tissue
form. The dry tissue
is stored in packaging suitable for long term storage.
It will be understood that the embodiments of the present invention described
hereinabove
are merely exemplary and that a person skilled in the art may make variations
and modifications
without departing from the spirit and scope of the invention. All such
variations and modifications
are intended to be included within the scope of the present invention.
72
